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CD8+ T cells display a little understood noncytolytic activity that suppresses human 
immunodeficiency type 1 (HIV-1) replication in an antigen-independent and MHC-unrestricted 
manner.  This activity specifically inhibits transcription of the HIV-1 proviral genome.  Little is 
understood about the molecular nature of the factor(s) mediating this potent antiviral activity of 
CD8+ T cells.  It is known that a factor secreted by CD8+ T cells can suppress the transcription 
of HIV-1. However, the antiviral mechanism appears most potent with cell-to-cell contact. 
Previous investigations by several groups into the nature of this secreted factor have been largely 
based on a presumption that noncytolytic suppression of HIV-1 by CD8+ T cells is exclusively 
mediated by a soluble protein.  Based on several lines of evidence suggesting the specific 
involvement of cell-contact determinants in eliciting the noncytolytic CD8+ T cell effector 
function against HIV-1, a novel approach to the problem was utilized based on the hypothesis 
that a membrane-bound factor is the prime mediator suppressing HIV-1 transcription.  In the 
ensuing investigation, evidence was uncovered demonstrating the existence of a membrane-
localized HIV-1 suppressing factor that was secreted as 30-100nm spherical vesicles termed 
exosomes.  Exosomes from a CD8+ T cell line inhibited the replication of R5 and X4 HIV-1 
isolates and were shown to specifically suppress HIV-1 transcription in acute and chronic models 
of infection.  A much greater degree of complexity to CD8+ T cell secreted antiviral activity was 
 iv 
found than a soluble protein alone could account for.  The evidence presented in this study 
suggests that CD8+ T cell suppression of HIV-1 is predominantly mediated by a membrane-
bound protein factor that can be cleaved into a soluble isoform with the secreted CD8+ cell 
antiviral activity being largely exosome-driven.  The results presented in this study provide a 
much more concrete understanding of the mechanisms underlying CD8+ T cells suppression of 
HIV-1 transcription and outline new approaches to conclusively identifying the molecular factor 
mediating potent inhibition of the HIV-1 transcriptional promoter. 
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PREFACE 
 
“…it was with those who had recovered from the disease that the sick and the dying 
found most compassion. These knew what it was from experience, and had now no fear for 
themselves; for the same man was never attacked twice -- never at least fatally. And such 
persons not only received the congratulations of others, but themselves also, in the elation of the 
moment, half entertained the vain hope that they were for the future safe from any disease 
whatsoever….”   
 
-  The Peloponnesian War by Thucydides, describing in 430 B.C. the phenomenon of 
acquired immunity to disease 
 
. 
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1.0  INTRODUCTION 
The disease progression of human immunodeficiency virus type 1 (HIV-1) infection to 
acquired immune deficiency syndrome (AIDS) is characterized by a progressive decline in CD4+ 
T cells (1,2,3), increasing viremia (4), and a downward inflection of total T-cell numbers 
preceding the onset of AIDS (5,6,7).  The inverse correlation between patient virus loads and 
length of time to development of AIDS from seroconversion (4,7) demonstrates that control of 
viral replication is a critical factor in long-term prognosis. In the last decade, the development of 
highly active antiretroviral therapy (HAART) has lead to a dramatic decrease in reported AIDS 
cases in countries where such therapy is available as standard care (8), however, the phenomenon 
of HIV-1 drug resistance and side effects from therapy are becoming increasingly problematic 
(9,10).  Of peculiar interest are a tiny percentage of HIV-1 infected subjects (<5%) who are able 
to maintain low or stable levels of virus replication in the absence of any intervening therapy or 
clinical symptoms of disease (11,12).  It is clear from such patients that their immune system is 
able to control HIV-1 replication and prevent disease progression to AIDS.  Therefore, an 
analysis of the immune response to HIV-1 may reveal insights into key molecular mechanisms 
that appear vital in controlling HIV-1 replication in these long term nonprogressing subjects.   
 
 1 
1.1 HIV-1 REPLICATION CYCLE 
HIV-1 belongs to a special subfamily of retroviruses known as lentiviruses (13).  The 
HIV-1 virion morphology consists of a conical shaped core contained inside a spherical 
phospholipid bilayer envelope (14).  The typical replication cycle of a virus begins with receptor-
mediated attachment of the virus to the host.  In HIV-1, the prime mediator of cell attachment is 
the viral gp120 envelope protein whose initial receptor target is the CD4 molecule expressed on 
CD4+ T cells and macrophages (15,16,17).  Upon CD4 binding, a conformational change occurs 
in gp120 resulting in the exposure of a chemokine receptor binding pocket encompassing a 
region of gp120 between the V3 and V1/V2 loop regions (18,19). HIV-1 displays two main 
chemokine receptor preferences, CCR5 (20) and CXCR4 (21). Strains that bind CCR5 are 
referred to as R5 isolates, while CXCR4 binding viruses are classed as X4.  The specificity of 
chemokine receptor binding defines HIV-1 cell tropism and syncytia inducing capability (20). 
Upon binding of CD4 and CCR5 or CXCR4, fusion of the viral phospholipid bilayer with the 
host cell membrane is mediated by the gp41 transmembrane protein (23,24), allowing for 
cytoplasmic entry of the HIV-1 ribonucleoprotein core.  
 
HIV-1 utilizes a peculiar genomic replication mechanism shared by all retroviruses 
known as reverse transcription (25). After disassembly of the core, the 9.8 kB mRNA genome is 
reverse transcribed into double stranded cDNA by the viral reverse transcriptase, RT (26). Upon 
completion of reverse transcription, the ds cDNA is translocated to the nucleus and integrated 
into the host genome by the HIV-1 integrase protein, IN (27).  After proviral integration, 
transcription of the HIV-1 genome is mediated with the aid of the virally encoded transcriptional 
transactivator, tat (28). Produced from an alternatively spliced HIV-1 transcript (29), Tat 
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mediates the recruitment of several critical nuclear proteins, such as CBP/p300 and CDK9 
(30,31), by binding to a double stranded RNA stem loop known as TAR that forms on 
transcribed HIV-1 mRNA between the +19 and +42 nucelotide region upstream from the HIV-1 
transcription initiation site (32). While the HIV-1 long terminal repeat (LTR) promoter contains 
binding sites for a wide array of cellular transcription factors, productive infection requires the 
binding of Tat to TAR in order to increase the processivity of the cellular RNApol II enzyme 
(33) and recruit the histone acetyl transferase activity of CBP/p300 to the LTR promoter in order 
to induce histone relaxation of the HIV-1 genome (34,35).  
 
Upon active transcription of the HIV-1 genome, viral structural and accessory proteins 
are translated to complete the replication cycle. The nuclear export of full length genomic and 
singly spliced HIV-1 RNA is mediated by the virally encoded Rev protein binding to the Rev 
responsive element RRE (36,37), located at the 3’ end of viral transcripts (38).  Translation of 
singly spliced HIV-1 RNA results in the protein fusion products Gag, Gag-Pol and Env (39). 
Upon translation of the Gag-Pol fusion protein, Gag is myristolated by N-myristyltransferase 
(40), for targeting to the plasma membrane while the viral protease, active in Gag-Pol, functions 
to cleave the fusion protein (41).  The viral protease proceeds in cleaving Pol into separate 
protease, reverse transcriptase, integrase products (41).  The viral Env is cleaved by a cellular 
protease to yield an extracellular glycosylated gp120 and transmembrane gp41 proteins (42) 
which are subsequently transported to the cell surface for virion assembly (43). Virion 
maturation occurs during and after budding of an HIV-1 particle, where the viral protease further 
cleaves the Gag into p24 capsid, p17 matrix, p6 proline-rich protein, and p7 nucleic acid binding 
protein (44).  
 3 
1.2 PATHOGENESIS OF HIV-1 AND PROGRESSION TO AIDS 
1.2.1 Clinical Stages of HIV-1 Infection 
HIV-1 disease pathogensis occurs in well defined stages (45). The first stage is 
establishment of acute infection after a transmission event whereby infection is seeded in 
primary lymphoid tissue (46). The acute stage, typically lasting on the order of 4 to 12 weeks 
(47), is characterized by a rapid proliferation of HIV-1 reaching peak viremia on the order of 105 
to 106 copies/ml (49). This initial burst of viral replication leads to a large depletion of the 
patient CD4+ T cell pool, particularly in mucosal lymphoid tissue (50).  The first detectable 
immune effector against HIV-1 is the CD8+ T cell response, the key immune effector mediating 
viral reduction during the acute stage of infection (51,52,53).  An antibody response against 
HIV-1 is usually detected by peak viremia (54) and together with the cellular immune effectors, 
serves to lower HIV-1 levels eventually establishing a baseline or setpoint viral load marking a 
transition to chronic infection and period of clinical latency (55).  It is at the onset of chronic 
infection that neutralizing antibody against the virus begins to develop (56). In the absence of 
drug therapy, the median time course of chronic HIV-1 infection before development of AIDS is 
8 to 10 years with patients displaying a vast continuum of disease progression rates from patients 
progressing to AIDS within 1-2 years to long term non-progressing subjects who remain disease 
free for 20 or more years (57).  In attempting to define the two clinical extremes, a striking 
correlation has been observed between HIV-1 viral load and the rate of disease progression to 
AIDS in therapy naive patients (3,4). This demonstrates clearly the importance host defenses 
against the virus play in the maintenance of healthy status in HIV-1 infected patients. 
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1.2.2 Long Term Non-Progressor (LTNP) HIV-1 Patients 
In attempting to define the parameters of host immune defenses critical to disease-free 
status in HIV-1 infected patients, significant attention has been focused on LTNPs.  Such 
individuals can be generally identified as therapy naïve and clinically asymptomatic for eight or 
more years with stable and healthy CD4+ T cell levels >500 counts per ml of blood (58).  The 
distinguishing immunological feature of these subjects is a strong adaptive immune response 
(59), particularly a strong cellular immune response (60,61,62).  Therapy naive LTNPs have also 
been observed to maintain reduced viral loads compared to rapid disease progressing HIV-1 
patients (4,63) indicating stronger host defenses in LTNP cohorts.  Stable CD4+ T cell counts 
and elevated CD8+ T cell levels distinguish LTNP subjects from rapid disease progressors 
(58,64).  Broad neutralizing antibodies are typically found in LTNP subjects (65) in addition to 
high amounts of HIV-1 specific CTL activity (60,61,62) and a less understood noncytolytic 
CD8+ T cell antiviral activity (66,67,68).  Such control of HIV-1 replication occurs in LTNPs 
independent of genetic factors such as previously described ∆CCR5 32bp deletion (69) and 
CCR2-64I (70) alleles.  Therefore, immunological control of HIV-1 is the most likely 
determinant of delayed disease progression in LTNP subjects. 
1.3 HOST IMMUNE RESPONSE TO HIV-1 
Asymptomatic HIV-1 infection can be roughly characterized as an ongoing conflict 
between the immune system and the virus infecting it.  Consequently, the breadth and quality of 
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the immune response during the acute and chronic stages of HIV-1 infection delineates the extent 
of viral replication control and consequently disease progression. The effector arms of the 
immune system can be broadly classified as innate or adaptive responses.  The innate immune 
response to pathogens include effector mechanisms such as complement activation (71), 
phagocyte induction through toll-like receptors (72) and other non-classical pattern recognition 
mechanisms (73), mircrobicidal peptide secretion (74), activation of pathogen-eliminating cells 
such as NK cells and granulocytes (75,76) and physical-chemical barriers to pathogen 
transmission (77).  The common feature of the innate immune system is a lack of memory of 
pathogenic protein sequences it encounters. The adaptive immune response on the other hand is 
defined by a direct association of antigen specificity and immunological memory. The adaptive 
immune response is comprised of two critical effector arms in pathogen control: (i) a humoral 
arm mediated by B cell antibody secretion to neutralize pathogen replication and induce their 
opsonization by phagocytic cells and/or direct lysis by complement activation (79);   and (ii) a 
cellular arm whose prime mediators are CD4+ and CD8+ T cells that function to control 
intracellular pathogen replication (80).   
 
As intracellular pathogens, most viral infections evoke a strong cellular immune response 
and this is especially true of HIV-1.  However, HIV-1 introduces a caveat in that it infects a 
subset of immune cells critical for immunity.  The infection of CD4+ T cells is a peculiar 
adaptation of HIV-1 replication, as these cells serve as a critical bridge between the humoral and 
cellular immune responses (80). Both of these adaptive immune responses are active in their 
efforts to control virus replication.  However, HIV-1 has proven itself notorious in its capacity to 
evade elimination by the host immune system.  Such persistent viremia is found even in LTNP 
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subjects, although these individuals maintain significantly lower viral loads than more rapid 
disease progressing individuals (4,63).  Thus, the nature of the adaptive immune response to 
HIV-1 appears to be the key determinant for delayed disease progression to AIDS (81,82).   
 
1.3.1 Humoral Immune Response 
B lymphocytes are the primary effectors of the humoral immune response.  Through the 
clonally derived specificity of the B cell receptor, these cells contribute to pathogen control via 
antigen specific antibody secretion.  Antibodies limit pathogenic infection by several 
mechanisms.  One function of antibody secretion is the clearance of a pathogen by direct binding 
to its surface, allowing for their opsonization and removal by phagocytic cells such as 
macrophages. Opsonization is also an important means of pathogen uptake by dendritic cells for 
presentation to T lymphocytes, a critical event for activating cellular immunity. Antibody coating 
of a pathogen is also a critical activator of the complement cascade which functions to control 
pathogens through direct lysis (83). In the case of HIV-1, however, the humoral response against 
the virus during the acute phase of infection has been found to actually play a role in the 
dissemination of virus as the process of antibody-dependent opsonization allows HIV-1 to 
specifically target lymphoid tissue sites containing the virus’ primary cellular hosts (84). The 
most effective mechanism by which the humoral immune response can control infection is 
through production of high titer antibodies that specifically inhibit or neutralize protein epitopes 
critical for infectivity (56). In HIV-1 infection, this involves blocking or inhibiting specific 
antigenic sites of the gp120 envelope protein critical to CD4 receptor and CCR5/CXCR4 
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correceptor binding, as well as external portions of gp41 critical to facilitating virus host 
membrane fusion (85,86,87,88).   
 
HIV-1, however, displays an array of measures to counter the antibody response.  For 
instance, the HIV-1 gp120 Env displays extensive glycosolation on its exterior protein surface to 
hide antigenic sites (89).  Epitopes critical to virus neutralization are often found buried within 
native interior structures of the gp120/gp41 complex (90).  A high degree of amino acid 
sequence variability is typically found on the exterior surface of gp120, largely representing the 
variable or V-loops of Env (89).  The extent of genetic hypervariability localized to HIV-1 Env 
sequences highlights the extreme capacity of the virus for mutational escape from the host 
antibody response (91).  Indeed, temporal studies of HIV-1 quasispecies, reveal a great 
divergence in HIV-1 sequences from seroconversion to the onset of disease (81,82).  There is 
evidence as well that antibody selection pressure is actually exploited by HIV-1 to enhance its 
replication as the variable loops in HIV-1 env appear to function as decoy antigens, promoting 
antibody-mediated targeting to Fc receptor expressing dendritic cells and macrophages in 
lymphoid tissue(92). 
 
A broad neutralizing antibody response has been noted in studies of several LTNP 
cohorts (54,93,94). Neutralizing antibodies, however, have been found to be slow in their 
development during HIV-1 infection and do not appear at significantly potent serum titers until 
after seroconversion (54).  This suggests that development of a potent neutralizing antibody 
response during asymptomatic infection is best promoted by a potent cellular response against 
the virus during the acute phase of infection.  This notion is supported by studies comparing the 
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cytokine milieu of LTNPs versus rapid progressing HIV-1 patients in which a bias towards a Th1 
type helper response, which favors cellular immunity, has been found to correlate with healthy 
status (95). A switch from Th1 to Th2 cytokine profile has been noted in several studies as a 
marker appearing to defining the onset of AIDS (96,97,98). Additionally, evidence has emerged 
that Th2 type cytokines, which help activate humoral immune responses, produce inflammatory 
conditions that promote Fas-mediated apoptosis of uninfected CD4+ T cells (99).  Thus, shifts 
towards humoral immune responses that are coincident with impaired cellular immune responses 
appear to compromise overall immunological control of HIV-1 infection. 
 
1.3.2 CD4+ T cell Response 
CD4+ T cells are distinguished from other immune cells by the specific expression of the 
CD4 molecule and T cell receptor specificity for peptides expressed in the context of MHC class 
II molecules.  CD4+ T cells, also referred to as “T helper” or Th cells, function to recognize 
peptide antigens derived from extracellular components of invading pathogens based on the 
clonally-derived specificity of their T cell receptors. These cells serve as a bridge between 
humoral and cellular immunity (100,101).  As such, two functional subsets of CD4+ T cell can 
be defined:  (a) Th1-type cells which mediate pathogen replication control by secretion of 
inflammatory molecules and (b) Th2-type cells which are critical activators of antigen-specific B 
cells (102).  A distinction between the two cell subsets can be made based on patterns of 
cytokine secretion. In Th1 cells, increased levels of IL-2, IL-12, and IFN-γ are typically detected 
and found to promote strong cellular immune responses, while Th2 responses result in increased 
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IL-4, IL-5, IL-6, and IL-10 cytokine secretion which functions to promote B cell differentiation 
and proliferation (103).   
 
CD4+ T cell concentration in blood been shown to inversely correlate with HIV-1 viral 
load (1,2,3), demonstrating the cytotoxic relationship HIV-1 infection has on CD4+ T cells.  The 
nature of HIV-1 cellular tropism and virus dissemination puts the virus in a position to 
preferentially target CD4+ T cells specific for HIV-1 antigen and thereby cause their accelerated 
depletion by virus-induced toxicity and/or immunological elimination (105,106).  While direct 
infection might account for much of the CD4+ T cell impairment during acute and asymptomatic 
infection, studies have demonstrated that HIV-1 also has more intricate adaptive mechanisms to 
counter a virus-specific T helper response.  One indication that HIV-1 actually modulates the 
CD4+ T helper response is the broad Th1 to Th2 switching that has been noted at the onset of 
AIDS (96,97,98).  While the mechanisms behind this are unclear, recent studies suggest that 
HIV-1 may be inducing biases towards Th2 responses by direct impairment of the Th1 response 
at the earliest stages of asymptomatic HIV-1 infection. In studies by Graziosi et al. (107) and 
Maggi et al. (108), peripheral and lymph node CD4+ T cells in unfractionated and pure 
populations were found to display no increases in gene expression of Th2 cytokines IL-4 and IL-
10 that correlated with advanced disease.   A third group corroborated this observation, however 
found instead a severe impairment in CD4+ T cell secretion of IL-12, a Th1 cytokine, at the 
earliest stages of asymptomatic disease (109).  Further investigation into the matter subsequently 
determined that HIV-1 infection itself actively downmodulates expression of IL-12 in CD4+ T 
cells, thereby directly impairing a Th1 response (110).  This explained data which demonstrated 
that infection of Th1 type CD4+ T cells promoted a switch from Th1 to Th0 (108), and it is Th0 
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and Th2 CD4+ T cells in which HIV-1 replication is most productive (108,111).  In such a 
manner, HIV-1 infection appears to directly impair development of Th1 responses at the earliest 
stages of disease, thereby steadily biasing CD4+ T cells towards Th2 type that serve to promote 
humoral immune effector functions.  
  
 Recent investigations have demonstrated further intricacies in HIV-1-induced 
impairment of Th1 type CD4+ T cell responses that appear to be important factors in disease 
progression.  A comparison of CD4+ T cell responses between HIV-1 and other viral infections, 
such as EBV and CMV, highlight dysfunctions of Th1 subsets that appear to be specific for HIV-
1 infection.  EBV and CMV are largely controlled by cellular immune responses. Within EBV- 
and CMV-specific Th1 CD4+ T cell response, three specific populations can be defined: (a) cells 
secreting IL-2 but not IFN-γ that are associated with conditions of antigen clearance, (b) cells 
secreting IFN-γ but not IL-2 that are typically associated with antigenic persistence and high 
viral loads, and (c) cells that doubly secrete IL-2 and IFN-γ which typifying maintenance of low 
viral loads in the face of persistent antigenic exposure (112).   In the case of HIV-1 infection, 
however, investigations have found that only in nonprogressing HIV-1 infected subjects are the 
three distinct Th1 subsets maintained among HIV-1-specific CD4+ T cells, while a decrease in 
the frequency of single IL-2 secreting and doubly secreting IL-2/ IFN-γ phenotypes is correlated 
with disease progression (113).  It remains to be determined whether the differential display of 
Th1 subsets between disease progressing and nonprogressing HIV-1 subjects is directly induced 
by virus or is simply a reflection of viral immunopathogenicity. Studies have demonstrated that 
HAART intervention results in enhancement of CD4+ T cell responses (114) and the restoration 
of polyfunctional Th1 CD4+ T cell subsets (113).  This would indicate that suppression of HIV-1 
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replication below a certain threshold is crucial for the development of effective CD4+ T cell 
responses against HIV-1. Hence, other effector arms of the adaptive immune system are likely 
critical for the emergence of protective T helper responses to HIV-1. 
1.3.3 Antigen-dependent CD8+ T cell response to HIV-1 
CD8+ T cells constitute the earliest detectable adaptive immune response to acute HIV-1 
infection (51,52) and are a critical factor in slowing the disease progression to AIDS (61,62).  A 
convincing demonstration of this can be found in studies of the Rhesus macaque AIDS model 
where in vivo depletion of CD8+ T cells during asymptomatic infection using monoclonal 
antibodies to CD8 leads to increased viremia and a more rapid progression to AIDS (115,116). 
Classically, T cell receptor recognition of peptides in the context of MHC class I molecules is the 
distinguishing feature of CD8+ T cells from their CD4+ cousins.  Presentation of antigenic 
peptide-MHC class I complexes and costimulation by dendritic cells is the defining event for the 
activation and clonal expansion of an antigen-specific CD8+ T cell immune response (117). 
CD8+ T cells have been well characterized for their ability to control viral pathogenesis by one 
of two effector functions: (i) antigen-dependent killing of virus-infected host cells by 
perforin/granzyme lysis (118) and Fas-mediated apoptosis (119), and (ii) release of antiviral 
cytokines (120).  However, a special case applies to HIV-1 immunopathogenesis as CD8+ T 
cells are also known to possess an antigen-independent effector mechanism against lentiviral 
replication (121,122).  Hence, a distinction is made here between the classical antigen-dependent 
effector mechanisms of CD8+ T cells (MHC Class I-restricted CTL activity and secretion of 
antiviral cytokines) and the noncytolytic antigen-independent CD8+ T cell response that is the 
subject of this study. 
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 1.3.3.1 A.  CD8+ cytotoxic T lymphocyte (CTL) activity 
 
A defining feature of cellular immunity is the CTL activity employed by CD8+ T cells to 
kill pathogen infected cells.  In CD8+ T cells, TCR recognition of antigenic peptide in the 
context of MHC class I molecules serves as the main trigger for a cascade of coordinated 
molecular interactions resulting in the polarization of the microtubule organizing center to 
facilitate fusion of lytic granules with the plasma membrane (123). Granular compartmental 
release leads to extracellular secretion of perforin, a cell membrane lysis protein with homology 
to complement protein C9 (124), and granzyme A and B proteins which both enter the cytoplasm 
of targets cells after perforin lysis (125).  Granzyme B promotes the cleavage of caspase 
activating a caspase-dependent apoptosis pathway (126), while Granzyme A activates a caspase-
independent apoptotic pathway (127).  The CTLs themselves are protected from cytoxicity by 
cathepsin B serine protease that is expressed on the membrane of lytic granules and translocated 
to the cell surface upon degranulation (128).  Upon TCR triggering, CTL also mediate target cell 
death through the cell surface expression of FasL that interacts with Fas/CD95 on target cells to 
induce yet another apoptotic pathway (119).   The localization of FasL on the periphery of TCR 
clusters is noteworthy as it is coincident with the same cell surface location of lytic granule 
fusion, suggesting that FasL and perforin/granzyme CTL functions are interdependent (129). 
1.3.3.2 B.  CD8+ T cell secretion of antiviral cytokines 
 
CD8+ T cells also elicit a second effector mechanism upon specific antigen-recognition:  
the secretion of inflammatory cytokines that serve in regulation of immune responses as well as 
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induction of pathogen-infected cells into limiting infection (130). In the case of viral infection, 
antigen-specific TCR triggering often leads to secretion of antiviral cytokines that induce target 
and bystander cells to activate intracellular pathways that recognize, and interfere with, common 
molecular signatures of viral replication (131).  A characteristic CD8+ T cell secreted cytokine 
marker is IFN-γ, which has been shown to be important in the control of hepatitis B virus (130) 
and herpes simplex virus type 1 (120). One of the proteins induced by IFN-γ signal transduction 
is the ubiquitously expressed kinase, PKR (131).  PKR functions in the recognition of double 
stranded RNA, a molecular motif present in many viral replication mechanisms, including HIV-
1.  PKR recognition of dsRNA leads to the protein’s autophosphorylation and dimerization. In 
this activated state, PKR induces several signaling pathways that can directly interfere with viral 
replication, including phosphorylation of eIF2-α to inhibit protein translation and inactivation of 
IKK leading to activation of NF-κB (132), a transcriptional activator of a variety of genes 
involved in inflammation, apoptosis, and cell cycle control (133).   
 
The PKR pathway is one of many antiviral pathways that can potentially inhibit HIV-1.  
However, the nature of this pathway illustrates a point about the nonlinearity of cytokine-induced 
responses that apply to all inflammatory molecules.  For while PKR promotes a shut down of 
host translation, it also induces NF-κB, a potent transcriptional activator HIV-1 employs to 
enhance its proviral gene expression (134).   The PKR pathway is one of several examples 
illustrating that the overall effect on viral replication by an inflammatory cytokine depends on 
the balance between intracellular signaling pathways that induce or inhibit the virus.  This may 
underlie inconclusive results investigators have found as to the effect of IFN-γ on HIV-1 
replication, as different studies have reported divergent results from stimulatory to inhibitory to 
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neutral for this cytokine.  Another example of this differential effect of cytokines on HIV-1 
infection is the TNF-α induced signaling pathway (135).  While TNF-α signaling through 
TNFR1 activates a caspase-dependent apoptosis pathway, TNF-α signaling via TNFR2 results in 
NF-κB activation (136).  In fact, exogenous addition of TNF-α to HIV-1 infected cultures has 
been found to have a stimulating effect on viral replication in CD4+ T cells and macrophages 
(137).   
 
Nonetheless, several CD8+ T cell-secreted cytokines mediating antiviral effects in vitro 
have been identified.  IFN-α, TGF-β, and IL-16 have all demonstrated inhibitory effects on HIV-
1 replication in CD4+ T cells and monocyte-derived macrophages (137).  In addition, IL-10 and 
IL-13 have been shown to induce antiviral effects on HIV-1 replication in macrophages (138).  
CD8+ T cells have also been demonstrated to secrete β-chemokines MIP-1α, MIP-1β, and 
RANTES (139), with their antiviral effects mediated by blocking CCR5 access to HIV-1 gp120 
(140).  However, these antiviral effects of CD8+ T cell secreted molecules should be taken in the 
context of complex network of cellular- and cytokine-mediated interactions that occur in 
response to HIV-1 infection in order to fully understand their overall effects on viral replication. 
That Th2 type environments confer a more stimulating environment over Th1 for HIV-1 
infection are an example of the complexities inherent in the analysis of CD8+ T cell secreted 
inflammatory mediators inhibiting virus replication (141). This is in addition to the many 
strategies employed by HIV-1 to hijack cytokine- and virus-induced signal transduction 
pathways for its own replication advantage (142,143,144).   
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1.3.3.3  C.  Evasion of Antigen-specific CD8+ T cell responses to HIV-1 
 
With an overwhelming body of evidence clearly demonstrating the critical importance of 
CD8+ T cell responses in the control of HIV-1 replication and delayed disease progression, 
perhaps the relative importance of CD8+ T cells might further be inferred from the breadth of 
evasion mechanisms HIV-1 employs to thwart CTL activity.  One of the classic mechanisms that 
HIV-1 has demonstrated in this capacity is mutational escape from antigen-specific responses.  
Several studies have documented instances of antigen-specific CTL-imposed selection pressures 
leading to subsequent HIV-1 genetic and amino acid changes that altering the presentation of the 
antigenic epitopes towards non-recognition by or non-presentation to CTLs (145-149). A recent 
analysis by John et al. (150) determined that at a population level, HIV-1 sequences changes 
tended to cluster in protein domains of minimal structural and functional constraint and were 
more frequently associated with patient HLA-specific MHC peptide binding domains.  The same 
study also noted a temporal correlation between HLA-defined HIV-1 sequence changes and 
changes in viral load (150).  Such findings are corroborated by other investigations suggesting a 
correspondence between heterozygosity at HLA-A, HLA-B and HLA-C loci and lower viral 
loads, presumably through presentation of a more diverse array of peptide antigens to CD8+ T 
cells than homozygosity at an HLA loci would allow (151).   
 
 Mutational escape under selection pressure, however, is not the only strategy 
employed by HIV-1 to evade the CD8+ T cell response.  The viral accessory protein Nef plays a 
very important role in this regard.  Nef has been shown to selectively downmodulate MHC class 
I molecules expressed from HLA-A and HLA-B loci but not HLA-C or HLA-E (152).  This 
selective downregulation of MHC class I molecules reduces the extent of HIV-1 antigen 
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presentation to CTLs while avoiding killing by NK cells that are triggered by the absence of 
HLA-C and HLA-E (153).  In such a manner, Nef plays a crucial role in minimizing a combined 
CTL and NK cytolytic response in order to maximize viral replication.  Nef appears to also be 
important for another mechanism of thwarting CD8+ T cell action by specifically interfering 
with CTL induction of apoptotic pathways.  Studies have demonstrated that Nef prevents 
spontaneous apoptosis mediated through the TNF-α apoptosis pathway (154).  Nef also interferes 
with Fas-induced cell death through inhibition of ASK1, a kinase participating in FAS and TNF-
alpha apoptosis (155).  Another point at which Nef interferes with apoptotic pathways is through 
the binding and inhibition of p21-activated complex and PI-3 kinase, preventing its interaction 
with the proapoptotic factor Bad (156).  Such a diverse function for Nef in minimizing the CD8+ 
T cell-induced cytolysis and apoptotic responses may be why infection with nef-deleted virus is 
coincident with a dramatically delayed disease progression to AIDS (157). 
 
While utilizing mutational escape and inhibition of host cell death for its replication 
advantage, HIV-1 also appears to employ more aggressive tactics against CD8+ T cells. In 
simian studies, Nef has been shown to increase FasL expression on the surface of infected CD4+ 
cells (158,159).  The HIV-1 transcriptional activator Tat has also been shown to promote FasL 
expression (160).  The viral gp120, particularly from X4 isolates, has also been demonstrated to 
induce expression of FasL and membrane-bound TNF-α (161).  The effects of HIV-1-induced 
FasL expression have been demonstrated to directly induce CD8+ T cell apoptosis in vitro and in 
vivo (162).   Through a wide array of mechanisms HIV-1 is able to not only evade the antigen-
specific CD8+ T cell response, but also employ tactics that promote the elimination of these cells 
over the course of chronic infection.   With such a chameleon-like capacity to evade antigen-
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dependent immune responses, an antigen-independent immune effector mechanism may be the 
key to effective control of HIV-1 infection and delayed progression to AIDS. 
 
1.3.4 Noncytolytic Antigen-Independent CD8+ T cell suppression of HIV-1 
Noncytolytic antigen-independent CD8+ T cell suppression of HIV-1 replication is the 
least understood CD8+ T cell effector mechanisms and represents a major gap in understanding 
the full correlates of immune protection against disease progression to AIDS.  Early in the AIDS 
epidemic, researchers studying clinical HIV-1 infection observed that the rate of HIV-1 disease 
progression appeared to correlate inversely with the ability to isolate virus from patient 
peripheral blood mononuclear cells (163).  A decisive study into the cause of this phenomenon 
was made by Walker et al. (121) in which the investigators demonstrated that CD8+ T cells were 
the critical component suppressing virus replication in PBMC in vitro. The authors demonstrated 
that CD8+ T cells could induce apparently complete suppression of virus when added to CD8+ 
cell-depleted PBMC from an HIV-1-infected patient compared to CD8-depleted cultures. 
However, upon removal of CD8+ T cells, viral replication rebounded to levels higher than 
infected CD8-depleted PBMC cultures alone. This suggested that CTL activity was not 
responsible for the near-complete suppression of virus, indicating a noncytolytic mechanism was 
being employed by CD8+ T cells to suppress HIV-1 (121).  In subsequent investigations by 
several groups, this noncytolytic mechanism was found to able to mediate potent suppression in 
HIV-1 replication in heterologous CD4+ targets in a non-toxic manner (164,165,166). A lack of 
MHC restriction was later confirmed for the activity (167,168,169), distinguishing it from the 
classical mechanism of cellular immunity.  The noncytolytic antiviral activity was further found 
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to be able to suppress in vitro replication of a broad spectrum of HIV-1 isolates (170,171), 
including X4 and R5 tropic viruses (172), further suggesting the effector mechanism was not 
antigen specific like CTL activity.   
1.3.4.1 A.  Activation of MHC-unrestricted CD8+ T cell noncytolytic HIV-1 suppression 
 
Several investigations have demonstrated a lack of noncytolytic HIV-1 suppression 
activity in CD8+ T cells from seronegative subjects that are readily detectable in most HIV-1 
patients at the earliest timepoints of infection (173,174,175).  More detailed temporal analysis 
during acute infection has demonstrated that noncytolytic suppression activity temporally 
coincides with the earliest detection HIV-1-specific CTL activity (51).  This suggests a priming 
mechanism might be involved in the development of noncytolytic CD8+ T cell suppression of 
HIV-1.  The nature of such a priming event for a noncytolytic anti-HIV-1 response is unclear, 
however its existence is partly supported by findings that noncytolytic HIV-1 suppressing CD8+ 
T cell populations exclusively display an activated HLA-DR+/CD28+ phenotype (176). It is 
unclear if such a development is functionally dependent on induction of CTL activity.  A study 
by Hsueh et al. (175) appears to suggest that general CTL activation may remove a regulatory 
barrier for propagation of noncytolytic CD8+ T cell clones.  These investigators reported that 
when primary CD8+ T cell clones were propagated by limiting dilution of bulk populations from 
seronegative subjects, a small percentage of clones exhibited readily detectable noncytolytic 
MHC unrestricted suppression activity against HIV-1 while bulk CD8+ T cell population 
displayed no such activity (175).  The authors further discovered that mixing of CD8+ HIV-1 
suppressive clones with an equal proportion of bulk CD8+ cells abrogated the suppressive 
activity of the clones beyond what would be expected from a dose-dependent response. These 
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results support the existence of a regulatory mechanism inhibiting the propogation of 
noncytolytic HIV-1 suppressive CD8+ T cell clones which may be removed by general CTL 
activation in response to primary infection (175).  Corroboration for this idea is provided by one 
study that detected potent noncytolytic HIV-1 suppression by CD8+ T cells from an EBV-
positive but HIV-1 seronegative subject (177). A second investigation additionally determined 
that clonal propagation of MHC-unrestricted noncytolytic HIV-1 suppressing CD8+ T cells is 
dissociated from CTL activity (178).  Thus, if antigen-dependent CTL priming is a trigger for 
activation of the antigen-independent anti-HIV-1 activity, it may likely be mediated through a 
bystander effect as dissociation between CTL activity and noncytolytic HIV-1 suppression 
activity can be readily detected in CD8+ T cell clones specific for non-HIV-1 antigens (179,180). 
1.3.4.2 B.  Mechanism of CD8+ antigen-independent suppression of HIV-1 replication 
 
Investigations into the molecular nature of the noncytolytic CD8+ cell HIV-1 suppression 
activity have revealed the dual involvement of a secreted factor and an apparent cell-contact 
dependent component in mediating the antiviral activity (172,181,182,183).  Initial studies had 
demonstrated that filtered CD8+ cell-conditioned culture fluids were able to elicit suppression of 
virus in secondary infectious CD4+ cell cultures (171).  The involvement of a secreted 
component was further supported by studies that demonstrated HIV-1 in vitro suppression of 
HIV-1 in CD4+/CD8+ cell co-cultures where infected CD4+ cells were separated from CD8+ T 
cells in a transwell system (181,183).  The secreted component mediating this activity 
maintained all the attributes of non-allogeneic restriction and lack of toxicity displayed by the 
cell mediated activity (181,182,183). However, transwell experiments readily identified an 
apparent cell contact-dependent component of the CD8+ T cell noncytolytic anti-HIV-1 activity. 
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Mackewicz and Levy (184) reported that transwell-mediated HIV-1 suppression required ten 
times the amount of CD8+ cells as CD4+/CD8+ cell-contacted to elicit an equivalent amount of 
suppression.  Similar findings by others (181) confirmed that cell-to-cell contact is the most 
efficient means for inducing maximum HIV-1 suppression.  Thus, a secreted factor appears to 
only contribute partially to the overall noncytolytic activity.  This is further indicated by findings 
that cell-contact mediated suppression is not necessarily coincident with secretion of an HIV-1 
suppressing factor (183) with the converse also having been demonstrated as well (185).  Taken 
together, these investigations suggest a mechanistic dissociation between cell-contact mediated 
suppression of HIV-1 and secretion of an antiviral factor (185).  
 
While distinct mechanisms may underlie cell contact- and secreted factor-mediated HIV-
1 suppression, a large body of evidence has revealed a single antiviral effector function linking 
the two.  It has been widely reported now that both CD8+ T cells and a factor secreted by them 
are able to suppress HIV-1 by specifically inhibiting proviral transcription (172,186,187,188).  
Among the evidence demonstrating CD8+ cell suppression of HIV-1 transcription are: (i) CD8+ 
T cell Inhibition of HIV-1 gene expression but not proviral integration or reverse transcription 
(177,189);   (ii) a temporal correlation of CD8+ T cell mediated HIV-1 suppression activity and 
potent inhibition of HIV-1 proviral transcription in a kinetic analysis of single cycle infectious 
assays (190);   (iii) CD8+ T cell inhibition of spliced and unspliced HIV-1 transcripts in 
endogenously-infected cells (186);   (iv) CD8+ T cell suppression of HIV-1 transcription in 
chronically infected but RT-defective 8E5 cell line (Chen and Gupta, unpublished data);  and (v) 
inhibition of both tat-induced and PMA-induced HIV-1 LTR promoter by CD8+ T cells (190) 
and a CD8+ cell secreted factor (172).  In particular, studies of HIV-1 suppression using LTR-
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gene reporter assays define the most imperative functional link between the CD8+ cell-mediated 
and secreted factor antiviral activities.  The suppression of PMA mitogen-induced LTR 
promoted transcription demonstrates that the antiviral mechanism specifically inhibits the viral 
LTR promoter and exclusively utilizes cellular and not viral proteins to mediate the suppressive 
effect since the LTR is efficiently repressed in the absence of HIV-1 Tat.  This clearly explains 
the non-antigenic and MHC unrestricted nature of the activity as presentation of HIV-1 antigen 
or viral protein expression is not a prerequisite for CD8+ T cells or the CD8+ cell-secreted factor 
to elicit inhibition of LTR promoter activity.   
 
 The exact intracellular mechanism mediating LTR promoter suppression under 
induction of CD8+ T cells is not fully understood.  In a study by Chang et al., the secreted CD8+ 
cell factor suppression of the LTR was found to dependent on STAT-1 induction of secondary 
genes, but not through a direct effect of STAT-1 on the LTR itself (172).  In a study of possible 
LTR promoter sequences involved in mediating the suppressive effect, 5’ deletions of the LTR 
up to the transcription start site did not appear to abrogate the action of noncytolytic HIV-1 
suppressive CD8+ T cells (Chen and Gupta, unpublished data).  The non-involvement of NF-KB 
and sp1 binding sites in the HIV-1 LTR promoter for CD8+ T cell inhibition of HIV-1 
transcription was additionally confirmed by Locher et al (170). These findings suggest that the 
LTR sequences involved in CD8+ cell-mediated HIV-1 promoter repression are located 
immediately downstream of the HIV-1 transcription initiation site.  This may represent an 
important clue for defining the intracellular signaling pathways CD8+ cells use to induce 
suppression of the HIV-1 promoter.   HIV-1 sequences overlapping the TAR region just 
downstream of the +1 transcription initiation site have been found to be involved in HIV-1 
 22 
transcriptional silencing leading to a latent infection state in CD4+ T cells (191).  Binding of 
nuclear factors LSF and YY1 to these DNA sequences leads to the recruitment of histone 
deacetylation enzymes to the HIV-1 transcription initiation site resulting in gene silencing by 
nucleosome compaction of LTR sequences (191).  If CD8+ T cells are able to induce such a 
pathway in CD4+ cells, it would represent a very potent mechanism of viral suppression as the 
HIV-1 TAR region has been shown to be very highly conserved (192) and TAR RNA stem loop 
function is very sensitive to sequence changes (193) making mutational escape of for the virus 
conceivably difficult.    
 
1.3.4.3 C.  Molecular Characterization of the CD8+ cell secreted HIV-1 suppressing factor 
 
In attempting to identify the molecular factors mediating the CD8+ T cell noncytolytic 
antiviral mechanism, many groups have focused on the soluble component of the activity, as it 
presents a much more practical means of biochemical elucidation than the challenges of 
identifying a cell-contact dependent component.  However, the field of literature surrounding the 
secreted CD8+ cell antiviral factor (CAF) is somewhat confounded by divergent definitions of 
what noncytolytic HIV-1 suppression actually entails.  Many investigators have defined their 
search for the elusive CAF based on biological assays that measure only inhibition of productive 
viral replication.  Such approaches had identified anti-HIV molecules such as β-chemokines 
(139), IL-16 (194), α-defensins (195), and antithrombin III (196).  However, subsequent 
investigations have revealed dramatic inconsistencies of these molecules to the hallmarks 
defining CAF activity.  β-Chemokines could only explain inhibition of R5-tropic HIV-1 binding 
to CCR5 (20,195), and subsequent investigations demonstrated that antibody neutralization of β-
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chemokines did not abrogate the suppression of both R5 and X4 viruses (197).  While IL-16 can 
induce suppression of HIV-1 LTR promoter activity (198), neutralizing antibody to this cytokine 
does not abrogate CD8+ T cell suppression of HIV-1 and CD8+ T cells have not been found to 
secrete IL-16 at high enough concentrations to explain the observed suppression (199).  α-
Defensins were originally proposed to account for inhibition of X4-tropic HIV-1 as part of a 
multifactorial hypothesis for CAF, however, it was later demonstrated that CD8+ T cells were 
not the primary cellular source of the secreted α-defensins (200).   The proposal of antithrombin 
III as a possible component of CAF activity was made upon purification of a serum factor that 
was specifically modified by CD8+ T cells to elicit anti-HIV-1 activity, however, this particular 
antiviral factor could only account for inhibition of X4 virus isolates (196).   
 
 At the present, no single known molecule has been show to fully account for CAF 
activity.  However, in the process of attempting to define such candidate molecules, a set of anti-
HIV molecules with variable inhibitory mechanisms had been identified. Thus, a hypothesis has 
been proposed by some that CD8+ T cell noncytolytic suppression of HIV-1 is due to 
multifactorial secreted components (201).  Such a hypothesis envisions that β-chemokines 
mediate R5-tropic viruses while X4-tropic viruses are inhibited by other factors such as 
antithrombin III (201).  However, a multifactorial hypothesis does not readily reconcile itself 
with evidence supporting the alternative view that the potency of noncytolytic CD8+ T cell 
suppression of HIV-1 is entirely due to the specific inhibition of the HIV-1 LTR promoter.  The 
existence of such a specific and potent antiviral mechanism would argue against a divergent set 
of molecular factors, particularly molecular candidates which directly interfere with HIV-1 
proteins. HIV-1 promoter inhibition in the absence of any other antiviral mechanism elegantly 
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explains all the hallmarks of noncytolytic HIV-1 suppression by CD8+ T cells without the 
caveats imposed by a proposal of multifactoral factors.  
 
However, defining a single molecular determinant that accounts for transcriptional 
suppression as the sole mechanism underlying potent CD8+ T cell suppression would require 
reconciliation of cell-mediated and secreted forms of the activity. The dissociation observed 
between cell-contact dependent and secreted forms of the antiviral activity would argue against 
the factor being a purely soluble protein mediator since potent CD8+ T cell contact-dependent 
suppression of HIV-1 can occur in the absence of any detectable secreted activity of the same 
form (185).  The alternative explanation would consequently be that the HIV-1 transcription 
suppressing factor exerts its activity through membrane-localized and secreted forms.  This 
theory begs for a mechanistic explanation as to how the proposed factor is both soluble and 
membrane-bound. 
 
To date, no cell surface molecule has been described for mediating noncytolytic HIV-1 
suppression.  Some attempts have been previously made to evaluate possible cell-contact 
determinants that mediate the antiretroviral transcription suppression activity.  Barker et al. (202) 
reported that antibody inhibition of CD80 and CD86 costimulatory molecules on CD8+ T cells 
did not abrogate their antiviral activity, but did produce a small enhancement to the overall 
CD8+ cell suppressive effect.  Mackewicz et al. (203), using a similar analysis, found that 
neither Fas nor FasL were involved in CD8+ cell noncytolytic anti-HIV-1 activity.  The same 
group also reported that noncytolytic CD8+ T cell suppression of HIV-1 was not due to 
granzyme A/B release (204,205).  The role of HLA-compatibility has also been evaluated by 
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several groups and found to only confer a slight enhancement of noncytolytic HIV-1 suppression 
activity when co-cultured CD8+ effector and infected CD4+ cells are autologous (168,169). One 
study also demonstrated that CD8+ T cell clones could display antigen-specific CTL activity and 
MHC unrestricted noncytolytic antiretroviral activity concurrently, though the two mechanisms 
were shown to be independent of each other (175). While these combined results are not 
surprising given the MHC-unrestricted nature of noncytolytic HIV-1 suppression, they remain 
the only reported analysis of any cell-contact factors in the context of noncytolytic HIV-1 
suppression by CD8+ T cells.   
 
The role membrane determinants might play in mediating noncytolytic CD8+ T cell 
suppression of HIV-1 transcription remains mostly unexplored.  Defining a membrane-localized 
antiviral factor has its inherent complexities. Physical tethering of a molecule to cell membrane 
subjects it to a restricted environment dictated by the intricacies of cellular compartmentalization 
and lipid domain trafficking between cell surfaces and various intracellular compartments. The 
immune synapse, the so-called C-SMAC/P-SMAC complex (206), is a classic example of 
membrane protein regulation in CD8+ T cells.  Another well known example is degranualtion 
during CTL activity, where TCR antigen recognition ultimately results in the translocation of 
normally sequestered intracellular membrane compartments to the cell surface (123).  Therefore, 
if noncytolytic HIV-1 suppression was mediated by a cell surface protein, then the antiviral 
factor would be subject to similar membrane regulations in CD8+ T cells. In other words, protein 
expression of an antiviral membrane factor alone may not necessarily elicit the antiviral activity 
at the cellular level.   
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There are some paradoxical aspects for a membrane-bound suppressor of HIV-1.  A 
mechanism must exist that allows the factor to appear in a secreted form.  The trivial case would 
be a peripheral membrane protein, existing in equilibrium between membrane-localization and 
soluble molecule.  A more intricate possibility is the factor being an integral membrane protein 
with a catalytically active domain that can be released by proteolysis.  An example of this 
mechanism is the cleavage of membrane-bound TNF-α (207) and Fractalkine (208) into soluble 
cytokines.  However, a more complex cellular machination that remains unexplored in CD8+ T 
cells may also account for secretion of a membrane-bound molecule  – the extracellular release 
of tiny spherical lipid bilayer vesicles termed exosomes (209).  This last possibility may be a 
more flamboyant theory for secreted CAF activity. However, it represents a phenomenon of 
eukaryotic cells that is gaining wider appreciation in the field of antigen presentation and tumor 
immunity (210).  Several studies have demonstrated the ability of cell-free dendritic cell- 
secreted exosomes to modulate T cell responses in vivo (211).  Such peculiar mechanisms are 
just beginning to be understood, as DC-secreted exosomes have been shown to harbor enriched 
amounts of functional peptide-loaded MHC class I and II molecules as well as other membrane-
bound factors that typically help mediate antigen-specific DC activation of T cells through cell 
surface contacts (212).  Thus, exosomes represent an intimate and functional connection between 
cell surface proteins and the specific endosomal membrane domains they are derived from.  
Accordingly, exosomes could provide a plausible mechanism for the appearance of cell-bound 
and cell-free membrane proteins that remains to be explored in CD8+ T cells.  In the absence of 
any identification of a soluble factor identifying with the hallmarks of CD8+ T cell noncytolytic 
HIV-1 suppression, an exploration into the uncharted realm of CD8+ cell membrane proteins 
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might provide a novel starting point to unraveling the mystery surrounding CAF and cell-
mediated suppression of HIV-1 transcription. 
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 1.4 STATEMENT OF THE PROBLEM AND GOALS OF THE STUDY 
The precise molecular mechanisms underlying noncytolytic CD8+ T cell suppression of 
HIV-1 transcription remain enigmatic.  The importance of this CD8+ T cell effector mechanism 
can be inferred by its correlation to delayed disease progression and healthy clinical status in 
LTNP HIV-1 infected subjects.  CD8+ T cell suppression of HIV-1 transcription represents a 
potent mechanism for inhibiting the virus due to the effector function’s antigen-independence 
and MHC-unrestricted nature.  However, a lack of insight as to the precise molecular 
mechanisms involved in this effector function has left a gaping hole in attempting to understand 
what the true correlates of protection against HIV-1 entail. No study to date has revealed the 
molecular identity of the factor mediating noncytolytic CD8+ T cell suppression of HIV-1.  
Despite clear evidence of cell-contact dependent suppression of virus, the role of membrane 
determinants in mediating CD8+ T cell suppression of HIV-1 has been largely unexplored.  An 
investigation was therefore undertaken to elucidate the molecular nature of this potent antiviral 
activity based on the hypothesis that CD8+ T cell suppression of HIV-1 is mediated primarily by 
a membrane-bound factor.  Preliminary work based on this postulate uncovered a membrane-
localized activity that demonstrated suppression of HIV-1 replication.  The goal of the ensuing 
study was to characterize this membrane antiviral activity and specifically determine if it 
identified with the hallmarks of CD8+ T cell noncytolytic HIV-1 suppression.  In doing so, an 
investigation into how the membrane-localized activity might be secreted was undertaken to 
determine its possible identity to secreted CAF activity.  The results of this study are presented in 
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the following two chapters.  A broader discussion of the investigation follows with a new 
interpretation of the molecular mechanisms underlying CD8+ T cell noncytolytic suppression of 
HIV-1 based on the discovery of a novel membrane-localized and exosome-secreted antiviral 
factor. 
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 2.1 ABSTRACT 
It has been well established that CD8+ T cells can suppress human immunodeficiency 
virus type 1 (HIV-1) replication by inhibiting its transcription from the 5’ long terminal repeat 
promoter (LTR).  This antiviral activity is mediated in part by a secreted CD8+ cell antiviral 
factor termed CAF whose molecular elucidation remains undetermined.  A potent membrane-
bound HIV-1 suppressing activity was identified and found to be secreted as 30-100 nm sized 
endosome-derived vesicles termed exosomes.  Biochemical analysis revealed the HIV-1 
suppressive activity was found to be elicited by an integral membrane factor with some results 
suggesting the existence of a soluble isoform.  Purified exosomes were found to suppress the in 
vitro replication of R5 and X4 isolates of HIV-1, inhibiting proviral transcription through the 
specific repression of LTR promoter driven gene expression in both acute and chronic models of 
infection.  The results of this investigation demonstrate a significant contribution of exosomes to 
secreted CAF activity in CD8+ cell-conditioned culture fluids, providing for the first time direct 
evidence functionally linking membrane-mediated cell-contact dependent noncytolytic CD8+ T 
cell suppression of HIV-1 with a secreted mediator of the antiviral activity. 
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 2.2 INTRODUCTION 
In the context of HIV-1 replication, CD8+ T cells display a most peculiar antiviral 
effector mechanism that is distinct from its more characterized role of antigen-dependent 
cytotoxic T lymphocyte (CTL) activity.  This rather unusual mechanism does not require major 
histocompatibility molecules (122,169), nor is expression of HIV-1 protein a prerequisite for the 
activity’s elicitation (172,187,188).  The target of this CD8+ T cell effector function is the 
repression of the HIV-1 LTR transcription promoter (170,172,188).  This proviral transcription 
inhibition is the likely explanation for why CD8+ T cells from HIV-1 infected subjects are able 
to suppress lentiviral replication regardless of virus co-receptor usage (172,190).  It may also be 
a major contributing factor to the striking correlation of long term asymptomatic status in certain 
HIV-1 infected subjects with the extent of noncytolytic antiviral activity displayed by their 
primary CD8+ T cells.  A secreted CD8+ cell antiviral factor, termed CAF, has been shown to 
partly mediate the overall HIV-1 transcription suppression observed in cell cultures 
(172,181,183).  However, no conclusive molecular identity has been made for this secreted 
antiviral activity and no known CD8+ cell-secreted molecule to date has been shown to 
conclusively identify with the hallmarks defining CAF- and CD8+ T cell-mediated noncytolytic 
HIV-1 suppression activity (182,199,200,239-241).   
 
The identification of the molecule(s) mediating CAF activity has proven problematic, 
primarily due to its secretion in low amounts in CD8+ cell culture supernatants (184).  A 
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technical development in the search for CAF has been the utilization of herpesvirus saimiri 
(HVS)-transformed CD8+ T cell lines.  Use of these immortalized CD8+ cells in the study of 
noncytolytic HIV-1 suppression activity has been widely reported with demonstrations of HVS-
transformed CD8+ T cell lines potently suppressing HIV-1 replication in a similar manner as 
primary CD8+ T cells (172,188,197,213,214).  The immortalized nature of HVS-transformed 
CD8+ T cell lines allows for their use in generating large quantities of CD8+ cell conditioned 
media for biochemical purification of the antiretroviral activity.  However, despite this 
advancement, attempts to purify the secreted anti-HIV factor from culture media using standard 
biochemical methods have yielded no conclusive results as to the identity of the molecule(s) 
involved in mediating the activity.  Part of the difficulty in such an endeavor is the decreased 
sensitivity and reproducibility of traditional in vitro HIV-1 infection assays in evaluating the 
antiviral effects of biochemically-extracted fractions.  This may be why inconsistent biological 
effects are often reported in the study of CD8+ T cell noncytolytic HIV-1 suppression 
(173,183,185).  Recently, Chen et al. (173) described a semi-quantitative HIV-1 suppression 
assay using pre-infected cryopreserved acutely infected primary CD4+ T cells in which viral 
replication has been pre-titrated for use in a standardized and highly reproducibly acute 
infectious assay.  This assay allows for analysis of CD8+ T cell HIV-1 suppression on a more 
sensitive micro-scale (1-5x104 infected target cells as opposed to other described assays typically 
utilizing 1x105 to 1x106 infected targets).  In a more recent development, Chang et al. (172) 
described a 48 hour gene-reporter assay that measures secreted CAF activity specifically at the 
level of HIV-1 LTR inhibition.  The assays described by Chen et al. (173) and Chang et al.(172) 
represent critical developments for quantitative detection of an antiviral activity found secreted 
in low amounts. 
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 Technical limitations alone, however, may not be the primary reason why the molecular 
identity of CAF has remained elusive.  Secreted CAF by itself may not play a significant 
physiological role in the overall CD8+ T cell antiviral effect as transwell studies have 
demonstrated that cell-contact is a far more efficient means for suppressing HIV-1 replication 
than a secreted mediator (184).  This would imply that determinants localized to cell membranes 
may be primarily responsible for mediating the noncytotoxic antiviral activity, especially since 
cell-mediated activity can be detected in the absence of a secreted factor (183).  Therefore, one 
reason why CAF purification has proven problematic may be the unexplored possibility that an 
integral membrane protein is primarily responsible for mediating the noncytolytic CD8+ T cell 
antiviral activity.  This hypothesis, however, would require a mechanistic explanation for how 
the activity appears in a secreted form.  One plausible model to explain the secreted component 
might be proteolytic cleavage of an active domain from an integral membrane protein akin to 
what is seen for TNF-α and Fractalkine secretion.  The possibility of such a proteolysis model 
was studied by Mackewicz et al. (183), who found that certain protease inhibitors appeared to 
abrogate CD8+ cell- and CAF-mediated suppression of HIV-1. However, this diminishment of 
HIV-1 suppressive activity was incomplete and inconsistent between CD8+ cell samples and 
CAF-containing culture fluids from different patient samples.  If the HIV-1 transcription 
suppressing factor is indeed an integral membrane protein, then the results of Mackewicz et al. 
(183) would suggest that the putative factor can suppress viral replication in the absence of its 
cleavage.  If that is the case, there may be another more intricate yet unexplored mechanism to 
explain the secretion of an integral membrane protein with HIV-1 transcription suppression 
activity. 
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 An alternative model that elegantly resolves the imparity of a secreted extracellular 
integral membrane protein is the cellular release of tiny membrane-limited vesicles termed 
exosomes (209).  Exosome secretion has been described for a variety of cell types (209,216-
219).  Exosomes originate intracellularly through a budding process that creates vesicular 
invaginations within late endosomes (209).  These budding lead to active formation of 
multivesicular bodies within the lumen of late endosomes that eventually form into the 30-100 
nm diameter spherical exosomes.  The exosome-containing late endosomes can undergo two 
fates: (i) fusion with lysosomes for degradation of intraluminal components or (ii) fusion with 
the plasma membrane leading to the extracellular release of vesicles (Figure 1).   
 
 
 
Figure 1.  Endosome cycling and exosome secretion.  Exosomes form by luminal  
invagination of late endosomes that result in the formation of multivesicular bodies 
(MVBs).  The MVBs have two possible fates, fusion with lysosomes or fusion with the 
plasma membrane. 
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The morphogenesis of exosomes in eukaryotic cells is thought to primarily function in 
the degradation of cellular membranes by substantially increasing the effective lumen surface 
area accessible to lysosomal enzymes (220).  However, an increasing body of evidence is 
beginning to suggest a variety of extracellular functions for these vesicles, particularly in the 
modulation of immune responses (218,219,221,222).  Proteomic analysis of exosomes from a 
variety of cell types has demonstrated the specific enrichment of MHC Class I and II in the 
vesicles in addition to co-stimulatory molecules crucial for mediating activation of T cells 
(212,223).  The most characteristic molecular signature of exosomes is their highly enriched 
tetraspanin protein content (223,224,225). These integral quadruple-spanning membrane proteins 
form distinct membrane protein clustering domains within cells that are analogous to but very 
distinct from lipid rafts (226).  One tetraspanin in particular, CD63, is a specific lysosomal 
marker that delineates the intracellular origin of these vesicles from the same endosomal lumen 
through which cell surface expression of MHC Class II molecules is also effected (225).  As 
such, exosomes provide a direct link between cell surface expression and extracellular secretion 
for a variety of membrane bound proteins. 
 
Therefore, a seminal investigation was undertaken to ascertain the existence of specific 
CD8+ cell membrane determinants mediating noncytolytic suppression of HIV-1.  Preliminary 
findings of potent HIV-1 activity in cellular membranes purified from CD8+ T cells prompted a 
more thorough evaluation of this activity’s mechanisms and physiological context.  In the 
ensuing study, evidence was uncovered demonstrating a direct mechanistic connection between 
cell-contact dependent and secreted factor- mediated HIV-1 antiviral activity through exosomes 
with the membrane-localized activity specifically inhibiting transcription from the HIV-1 LTR 
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promoter, a hallmark of CAF- and CD8+ cell-mediated noncytolytic antiretroviral activity. A 
significant contribution of exosomes to secreted CAF activity was uncovered along with 
evidence suggesting the concurrent existence of a membrane- and soluble- form of the HIV-1 
transcription suppression activity. These results suggest that the complexity of CAF may not be 
the result of multifactorial cytokine secretion but due to a finite antiviral factor that is secreted in 
a membrane-bound vesicular form. 
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 2.3 MATERIALS AND METHODS 
Cell lines and Virus Stocks 
 The transformation of primary CD8+ T cells with herpesvirus saimiri (HVS) has been 
previously described (197). We utilized a particular HVS-transformed CD8+ T cell clone, TG, 
which was derived from primary CD8+ T cells purified from the peripheral mononuclear blood 
cells (PBMC) of an AIDS patient and transformed as previously described (197).  Primary CD4+ 
T lymphocytes were selectively enriched as previously described (173) by immunomagnetic 
bead depletion of CD8+ cells from PBMC donated from an uninfected seronegative donor.  
Primary CD8+ T cells from two asymptomatic HIV-1 infected subjects were obtained through 
the Multicenter AIDS Cohort Study (MACS) at the University of Pittsburgh.  The TZM-bl cell 
line was obtained through the NIH AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH from Dr. John C. Kappes, Dr. Xiaoyun Wu and Transzyme, Inc. The 8E5 
cell was obtained through the NIH AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH from Dr. Thomas Folks.  TG, 8E5, H9, Raji, U937, primary CD4+ and 
CD8+ T cells were cultured in growth medium consisting of 20% FCS/RPMI supplemented with 
25 mM HEPES and penicillin/streptomycin.  TG cells and primary CD4+ and CD8+ T cells were 
supplemented with 5 U/ml of recombinant IL-2 (Roche, US).  TZM-bl cells were cultured in 
10% FCS/DMEM supplemented with penicillin/streptomycin.  The M-tropic (R5) HIV-1 isolate 
33015 was derived from an HIV-1 infected long-term nonprogressor patient from the MACS. 
The T-tropic (X4) HIV-1 isolate 33074 was obtained from an HIV-1 infected rapid progressor 
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patient from the MACS. Immunomagnetic beads (Dynal, Norway) were utilized for cell 
separation (anti-CD8 antibody coated beads) and exosome phenotyping (anti-MHC class II 
antibody coated beads). For exosome phenotyping by flow cytometry, fluorescently-labeled 
monoclonal anti-CD9, anti-CD63, anti-CD81, anti-CD14, and anti-CD34 and control isotype 
mouse IgG1 antibodies (Research Diagnostics Inc., US) were utilized. 
 
Semi-quantitative Acute Infectious Suppression Assay 
 Suppression of acute HIV-1 infection was assayed using a semi-quantitative acute 
infectious suppression assay essentially as described by Chen Y et al. (173). Peripheral blood 
mononuclear cells were isolated from an uninfected seronegative subject by ficoll-hypaque. 
Anti-CD8 antibody coated immunomagnetic beads (Dynal, Norway) were used for separation of 
CD8+ and CD8- populations. CD8-depleted cells were cultured for six days in the presence of 
OKT3 and rIL-2 to expand and enrich for CD4+ T cells. After stimulation, cells were pretreated 
for 1 h with 5 µg/ml polybrene, washed, and incubated with either HIV-1 R5-tropic 33015 strain 
or X4-tropic 33074 strain of HIV-1 for 2 h.  Cells were washed after infection and cultured for 2 
days in 20% FCS/RPMI with rIL-2.  Cells were then DMSO-cryopreserved for use as target cells 
in an acute infectious suppression assay. A standardized protocol for measuring the HIV-1 
suppression activity of a sample was performed by thawing the crypreserved HIV-1 infected 
CD4+ cells and coincubation of TG cells or derived biological sample. HIV-1 suppression 
activity of the sample was measured five days later as the percent reduction in extracellular p24 
gag production, as measured by ELISA of culture fluid. This assay has demonstrated a high 
degree of standardization and reproducibility (173,197). 
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Preparation of cell membrane 
TG cells were harvested from culture, and cell pellets were made containing 1x108 to 
5x108 million cells over the course of TG cell culture and stored at -70 ºC until preparation of 
membrane. Frozen pellets were thawed and resuspended into STM solution (sucrose, tris-HCl, 
MgCl2) and subjected to three additional freeze-thaw cycles using ethanol/dry ice for freezing 
and thawing in a 37°C waterbath.  The disrupted cell suspension was homogenized using a 
Dounce homogenizer and the homogenate was clarified by centrifugation at 800xg at 4ºC to 
remove large cellular debris.  Supernatant from this spin was then subjected to 
ultracentrifugation at 60,000xg for 30 minutes to pellet raw cell membranes.  The pellet was then 
resuspended, overlayed on a 75% sucrose density cushion and recentrifuged at 90,000xg at 4 ºC 
for 1.5 h. The band above the 75% sucrose interface was extracted, washed in STM buffer, re-
pelleted by centrifugation, and resuspended in HBSS or RPMI. Protein concentration was 
measured using the BioRad Protein assay. 
 
Purification of exosomes  
Exosomes and other membrane fractions were harvested from culture supernatants by an 
adaptation of methods previously described (227,228) involving serial centrifugation of culture 
supernatant followed by sucrose density gradient purification.  Conditioned culture fluid from 
TG cell cultures was harvested and first subjected to centrifugation at 300xg for 10 min to 
remove cells. The supernatant was then subjected to serial centrifugations of increasing 
centrifugal force to derive depleted-supernatants and membrane pellets at 800xg for 30 min, 
6,000xg for 30 min, 15,000xg for 30 min, and 60,000xg for 1 h with all spins performed at 4 ºC.  
In such a manner, secreted membrane vesicles were derived at each centrifugation step with 
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smaller vesicles pelleted at increased centrifugal force. As exosomes typically pellet at 
centrifugal force >10,000xg (227), the 15,000xg pellet was utilized for harvesting exosomes to 
avoid contamination with serum protein complexes from the culture media.  A discontinuous 
sucrose density gradient separation was employed consisting of fractionation of the resuspended 
15,000xg membrane pellet through a two layer sucrose column consisting of a 40% sucrose (1.14 
g/ml) layer overlayed over a 60% sucrose (1.21 g/ml) cushion at 4ºC.  After centrifugation at 
28,000xg/4ºC, membrane fractions banded over the 40% and 60% sucrose interfaces and were 
extracted for further analysis and confirmation of exosome isolation in the 60% sucrose density 
fraction.  Sucrose fractions were washed in HBSS, pelleted by centrifugation at 18,000xg and 
resuspended in HBSS.  Protein concentration was measured using the BioRad assay. For other 
cell lines in this study, such as primary CD4+ T cells, H9, Raji, 293T, and HeLa, exosomes were 
prepared from culture fluids from these cells by the same method used to harvest exosomes 
secreted by TG cells. 
 
Transmission Electron Microscopy  
Copper grids (200 mesh) were formvar coated using 0.125% formvar in chloroform and 
floated on a drop of a highly concentrated exosome sample for approximately 30 seconds.  The 
grids were removed and excess sample solution was wicked away with filter paper, then placed 
on a drop of 0.45 µm filtered 1% uranyl acetate in de-ionized ddH2O (dI- ddH2O)  for 30-60 
seconds.  Excess stain was wicked away and samples were viewed on a JEOL JEM 1210 
transmission electron microscope at 80 kV.  Exosomes that were attached to immunomagnetic 
Dynal beads were pelleted at 500xg in a 1.5 ml microfuge tube and fixed in 2.5 % glutaraldehyde 
in PBS for 1 h.  Pellets were washed three times in PBS then post-fixed in 1% OsO4, 1% 
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K3FE(CN)6 for 1 h.  Following 3 additional PBS washes, the pellets were dehydrated through a 
graded series of 30-100% ethanol then infiltrated in Polybed 812 epoxy resin (Polysciences Inc, 
US) for 1 h.  After several changes of 100% resin over 24 h, pellets were embedded in a final 
change of resin, cured at 37ºC overnight, followed by additional hardening at 65ºC for two or 
more days.  Ultrathin (70 nm) sections were collected on 200 mesh copper grids, and stained 
with 2% uranyl acetate in 50% methanol for 10 minutes followed by 1% lead citrate for 7 
minutes.  Sections were viewed using JEOL JEM 1210 transmission electron microscope at 80 
kV. 
 
Flow Cytometry Analysis of Exosomes 
Flow cytometry analysis of exosomes was adapted from methods previously described 
(232).  Anti-MHC class II antibody coated immunomagnetic beads (Dynal, Norway) were used 
to capture exosomes by incubation of high concentration vesicle sample (as determined by 
protein concentration) with 2.5 x 105 beads. Bead-captured vesicles were washed twice in cold 
buffer (4% FCS/PBS) and incubated with 10 µg/ml of anti-CD9, anti-CD63, anti-CD81, anti-
CD14, anti-CD34, or isotype control biotinylated mouse IgG1 monoclonal antibody (R&D 
systems) for 30 minutes at room temperature. Beads were washed twice in cold buffer and 
incubated for 15 minutes room temperature with 1:50 diluted straptavidin-phycoerythrin 
conjugate (Invitrogen, US).  After a third round of washing, beads were fixed in 1% 
paraformaldehyde and analyzed on a Beckman Coulter EPICS XL.MCL Flow Cytometer.  
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Protease Treatment 
Aliquots of containing 60 µg of TG exosome were pelleted by centrifugation at 17,000xg 
and resuspended in 1 ml of 5 µg/ml trypsin or 1 ml of 5 µg/ml Trypsin + 5 µg/ml 
Chymotrypsinogen A or control exosomes resuspended in HBSS as a control.  Protease 
treatments and controls were incubated at 37 ºC for 6 h.  Protease-treated exosomes and control 
were then pelleted by centrifugation, washed with HBSS and resuspended in 300 µl of culture 
media (20% FCS/RPMI).   
 
Delipidation of Exosomes 
Exosomes were pelleted by centrifugation. In one experiment, delipidation of exosomes 
was performed by the Bligh and Dyer method (233).  Pelleted exosomes were resuspended in a 
2:1 mixture of chloroform/methanol, resulting in extraction of lipids into chloroform phase, 
proteins into the methanol solution and an insoluble precipitate at the chloroform/methanol 
interface.  The three fractions were extracted and dried for further analysis.  In a second 
delipidation method, cold acetone (-20 ºC) was used to dissolve exosomes and precipitate 
membrane protein.  Precipitated proteins were resuspended into RPMI, centrifuged for 5 minutes 
at 17,000xg to separate undissolved proteins from those remaining in solution.  Undissolved and 
dissolved proteins after acetone delipidation were analyzed for HIV-1 suppression activity.  
 
Acute HIV-1 Transcription suppression assay 
 An assay for measurement of LTR promoter inhibition in a model mimicking acute 
infection was adapted from the methods of Chang et al (172).  TZM-bl cells were seeded 25,000 
cells/well and cultured at 37 ºC for 24 h.  TZM-bl cells were then incubated with TG exosomes 
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or culture fluid sample for 16-24 h at 37 ºC.  Cells were washed twice with media prior to LTR 
activation.  For gene-reporter expression induced by virus infection, TZM-bl cells were 
inoculated with HIV-1 primary isolate 33015 and supplemented with 8 µg/ml DEAE-dextran for 
1 hour, washed with media and incubated at 37 ºC for 24 h after infection.  For Tat-transactivated 
LTR induction, TZM-bl cells were liposome-transfected with the Tat-expressing plasmid pSVtat 
using the Lipofectamine 2000™ reagent according to the manufacturer’s instructions 
(Invitrogen, US). For mitogen-activation of the LTR promoter, TZM-bl cells were incubated 
with 100 ng/ml PMA (Invitrogen, US) for 12 hours.  The extent of LTR-induced gene expression 
of β-galactosidase was measured using the β-GLO™ Assay (Promega, US). 
 
Chronic HIV-1 Transcription suppression assay 
 8E5 cells were incubated in the presence or absence of TG exosomes over a time course 
of 26 days. Cell numbers were maintained between 5,000 and 50,000 cells per well in a 96 well 
plate and cell numbers were adjusted every 5-7 days with replenishment of media alone or media 
supplemented with TG exosomes. At each 5-7 day timepoint, 1000 cells were collected and 
intracellular HIV-1 RNA copies per 1000 cells was measured using a standardized NASBA-
based HIV-1 RNA quantification assay (Organon Teknika). 
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 2.4 RESULTS 
2.4.1 Membrane from the CD8+ T cell line, TG, suppresses HIV-1 Replication 
While CD8+ T cell noncytolytic suppression of HIV-1 has been previously described as 
mediated by soluble factors, experiments in which CD8+ T cells and HIV-1 infected CD4+ cells 
are separated by a semi-permeable membrane demonstrate that this antiviral mechanism is most 
efficient with cell to cell contact. Therefore, a seminal experiment was performed to determine if 
membrane protein derived from CD8+ T cells could suppress HIV-1 in a similar manner 
observed with cell-mediated suppression.  The TG CD8+ T cell line was grown to a sufficiently 
large quantity for cell membrane purification.  The TG cell line itself displayed potent dose-
dependent HIV-1 suppression activity against acutely infected primary CD4+ T cells (Figure 
2A).  Cell membrane was purified from this cell line and was found to also mediate the same 
dose-dependent noncytolytic and nontoxic HIV-1 suppressive effect in an acute infection assay 
(Figure 2B).  A temporal kinetic analysis of TG cell and membrane suppression of HIV-1 
replication was performed by assessing the % suppression of HIV-1 replication over a time 
course of 0 to 96 h using HIV-1 p24 timepoints at 24 h intervals.  TG cell and purified TG 
membrane was consequently found to suppress HIV-1 replication with equivalent kinetics 
(Figure 2C), suggesting a common antiviral mechanism underlying both means of noncytolytic 
HIV-1 suppression. 
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  A.                 B. 
              
 
C.                D. 
            
 
Figure 2.  Dose-dependent suppression of HIV-1 replication in acutely infected 
CD4+ T cell by the TG CD8+ T cell line (A) and by membrane purified from TG cells (B). 
TG cells (Blacks Squares) and purified TG membrane (White Triangles) displayed 
equivalent time kinetics in suppressing replication of HIV-1 (C). The activity was tightly 
associated with the membrane as sodium carbonate treatment only moderately diminished 
membrane mediated HIV-1 suppression (D). 
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Since a secreted factor has been previously described as one of the defining 
characteristics of noncytolytic HIV-1 suppression activity by CD8+ T cells, an effort was made 
to discern if the TG membrane-mediated HIV-1 suppression activity was mediated by a 
peripheral membrane protein.  Purified TG membrane was treated with 0.1 M sodium carbonate, 
pH 11.5, to deplete peripheral proteins from the membrane. After treatment, membrane was 
pelleted by centrifugation at 17,000xg, washed, resuspended in media, and assayed alongside an 
untreated control for dose-dependent HIV-1 suppression activity.  A moderate decrease in 
membrane-bound HIV-1 suppression activity of 32% was detected after sodium carbonate 
treatment of TG membrane at the lowest dose assayed (Figure 2D), indicating that the majority 
of the antiviral activity still resided in the membrane after treatment, a result consistent with the 
presence of an integral membrane factor suppressing HIV-1. 
2.4.2 TG cell-secreted membrane vesicles suppress HIV-1 replication 
To account for the membrane-bound nature of the antiviral activity and its reported 
appearance in a secreted form, we hypothesized that this activity might be released in a vesicular 
form by CD8+ T cells.  This was based on the reasoning that if the CD8+ cell surface contained 
an HIV-1 suppressive activity, then vesicles secreted by TG cells would likely carry a portion of 
the same membrane determinants found on the cell surface and consequently also suppress HIV-
1 replication.  The secreted vesicles reported in the literature have been described as two general 
types: (i) 1 uM sized microvesicles originating from the plasma membrane and (ii) 30-100nm 
sized exosomes originating intracellularly from endosomal compartments (228).  Therefore, an 
investigation was conducted as to whether the TG cell line might also be secreting similar 
vesicles containing HIV-1 suppressive activity. Conditioned media from our TG cell cultures 
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was subjected to increasing serial centrifugation to derive membrane pellets of decreasing size. 
In such a manner, fractions of 6000xg, 15000xg, and 60000xg pellets were collected from cell-
free culture media of TG cells and standardized by volume.  These fractions were assayed for 
suppression activity using the acute infectious suppression assay and found to contain potent 
HIV-1 suppression activity peaking at 96% suppression for the 6000xg fraction and 87% 
suppression for the 15000xg fraction (Figure 3A).  To verify whether these peak TG culture 
supernatant membrane fractions also maintained the same integral membrane anchoring of HIV-
1 suppression activity that bulk TG membrane displayed after removal of peripheral proteins, the 
6000xg and 15000xg fractions were treated with 0.1 M sodium carbonate in the same manner 
done for bulk membrane, and after assaying for HIV-1 suppression, no significant diminishment 
of antiviral activity was found upon removal of peripheral proteins in either fraction (Figure 3B). 
This further corroborated the existence of an integral membrane factor mediating HIV-1 antiviral 
activity.  
 
As these extracellular membrane fractions clearly contained a tightly bound HIV-1 
suppressive activity, elucidation of their intracellular origin was sought in order to determine the 
functional nature of the membrane bound activity.  A good candidate for these membrane 
vesicles appeared to be exosomes as they typically pellet at centrifugal force greater than 
10000xg (227,228). Therefore, a 15000xg extracellular membrane sample was prepared and 
fractionated using a discontinuous sucrose gradient consisting of a layer of 40% sucrose over a 
60% sucrose cushion. The sucrose gradient was based on previous methods that demonstrated 
exosomes being harvested within a 1.14-1.21 sucrose density gradient range (227,228).   
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  A.                   B.  
              
C.                                                                                
                
 
Figure 3. HIV-1 suppression activity in TG secreted vesicles:  (A) Serial centrifugation of 
secreted vesicles.  (B) sodium carbonate treatment did not diminish the HIV-1 suppressive 
activity of the 6000xg nor the 15000xg TG supernatant pellets. (C) Sucrose density 
fractionation of 15000xg pellet with peak antiviral activity in the 60% sucrose density 
fraction.   
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After fractionating the 15000xg sample, two distinct bands were harvested, one pelleting at the 
40% sucrose  interface   representing   densities of        1.0-1.14 g/ml  and  a  second  band  pelleting 
at the 60% sucrose interface representing densities in the 1.14-1.21 g/ml range. The two fractions 
were washed, pelleted, resuspended in HBSS, standardized to equivalent protein concentration, 
and assayed for HIV-1 suppression activity.  Potent antiviral activity suppressing HIV-1 
replication by 95% was specifically observed in the 1.14-1.21 g/ml extracellular membrane 
fraction purified from the membrane band floating above the 60% sucrose density cushion, with 
only 15% HIV-1 suppression observed in the 40% fraction (Figure 3C). 
   
2.4.3 Identification of HIV-1 suppressing TG vesicles as exosomes 
The specific localization of HIV-1 suppression activity to the 60% sucrose density 
fraction is significant as it corresponded to the sucrose densities previously reported for 
exosomes secreted by other cell types (223,225,227,242).  We therefore sought to elucidate the 
identity of these TG secreted particles.  A fresh 15000xg/60% secreted membrane sample was 
prepared for analysis by transmission electron microscopy (TEM).  TEM revealed the highly 
enriched presence in the 15000xg/60% sample of vesicles resembling the 30-100nm size and 
spherical morphology of exosomes, as previously described for a variety of other cell types 
(Figure 4).   
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Figure 4.  Transmission Electron Micrograph of the 15000xg / 60% TG supernatant vesicle 
fraction.  The legend in the bottom left corner indicates magnification at 40,000 X with the 
white bar indicates a 100 nm measure. 
 
 
In order to confirm the identity of these TG vesicles as exosomes, a recently described 
exosome bead-capture technique (232) based on the enriched presence of MHC Class II 
molecules on the endosomally derived vesicles was employed. The bead-capture technique 
utilizes immunomagnetic beads coated with antibodies specific for MHC Class II molecules. By 
saturating the surface of the 4.5 µm diameter beads with the nanovesicles, the antigenic content 
of these vesicles can then be probed to confirm the presence of specific exosome markers.  The 
15000xg/60% vesicle fraction was incubated with anti-MHC class II immunomagnetic beads at 
4°C overnight after which the beads were magnetically isolated and washed.  Two aliquots of 
beads after vesicle incubation were made, one for electron microscopy analysis to confirm bead 
capture and the second aliquot for determining the antigenic content by flow cytometry.  
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Analysis of the immunomagnetic beads by ultrathin section electron microscopy revealed the 
saturation of the bead surface with the tiny vesicles, confirming their attachment to the beads 
(Figure 5A).  A separate aliquot of the bead-captured vesicles was subsequently analyzed by 
flow cytometry to dissect their antigenic content using specific monoclonal antibodies specific 
for exosome markers.  The specific presence of CD9, CD63, and CD81 was detected on the TG 
vesicles attached to the beads (Figure 5B, 5C, and 5D respectively) with CD63 producing the 
highest fluorescence shifts (Figure 5C).  CD14, a macrophage marker, was not detected for these 
vesicles (Figure 5E) while only moderate amounts of CD34 (Figure 5F) were observed.  In 
addition, antibody staining of control beads did not produce any fluorescence shift in control 
experiments (data not shown) indicating that the fluorescence shift relative to isotype control 
detected for CD9, CD63, and CD81 were specifically due to the presence of markers expressed 
on the vesicles attached to the beads.  CD9, CD63, and CD81 belong to the tetraspanin family of 
proteins and have been found to be highly enriched in exosomes from a variety of cell types 
(212,243). Additionally, CD63 is a specific lysosomal marker that also traffics to endosomal 
compartments (229,230), so its high expression on the vesicles relative to other markers indicates 
their specific endosomal origin.   Accordingly, the combined tetraspanin enrichment, endosomal 
origin, density in sucrose, size and morphology of these HIV-1 suppressing vesicles specifically 
identify them as TG cell-secreted exosomes with potent HIV-1 suppressive activity. 
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B.                                  C.                                  D.  
                   
 
E.                F. 
           
 
Figure 5.  Analysis of 15000xg / 60% sucrose gradient TG vesicles by immunomagnetic 
bead capture. (A) Ultrathin section electron microscopy of anti-MHC Class II antibody 
coated immunomagnetic beads after incubation with the TG vesicles – an enlarged section 
is presented on the right with arrows pointing to exosomes, the broad dashed lines 
representing the bead perimeter, and the black bar as a 100 nm measure. (B to F) Flow 
cytometry analysis of the same vesicle-coupled beads for detection of (B) CD9,   (C) CD63,   
(D) CD81,   (E) CD14,   (F) CD34. 
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2.4.4 TG exosome suppression of R5 and X4 isolates is protein mediated 
A hallmark of noncytolytic CD8+ T cell suppression of HIV-1 is the inhibition of CCR5-
tropic and CXCRX4-tropic HIV-1 replication (172).  The TG exosomes were, therefore, assayed 
for their ability to suppress two patient derived HIV-1 isolates: (i) 33015, an R5 clinical isolate 
and (ii) 33074, an X4 clinical isolate.  Using an acute infectious suppression assay, TG exosomes 
suppressed replication R5 and X4 HIV-1 isolates by 87% and 83% respectively (Figure 6A), 
demonstrating suppression of HIV-1 regardless of co-receptor usage.  The same analysis was 
made for exosomes from a second and third independent TG cell culture, this time assaying both 
exosome- and cell-mediated suppression of R5 and X4 HIV-1 replication.  In the second 
independent TG culture, both exosomes and cells were found to suppress HIV-1 replication 
regardless of viral tropism (Figure 6B), with exosomes suppressing R5 and X4 replication at 
44% and 42%, respectively, and with cells suppressing R5 and X4 replication at 85% and 81%, 
respectively.  However, in the third independent TG culture, only the exosomes were found to 
suppress both R5 and X4 HIV-1 replication at 35% and 40%, respectively, with no antiviral 
activity displayed by the cells from this culture (Figure 6C). This third independent TG culture 
demonstrated a clear dissociation between exosome- and cell-mediated HIV-1 suppression 
activity (Figure 6C) in a similar manner to what has been observed for CAF (183,184). 
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igure 6. TG exosome suppression of R5 and X4 isolates.  (A) TG Exosome suppression of 
IV-1 isolates 33015 (R5) and 33074 (X4).  (B) TG exosomes and cells from a second 
dependent culture suppress replication of R5 and X4 HIV-1 isolates.  (C) TG exosomes 
F
H
in
from a third independent culture suppress R5 and X4 HIV-1 isolates, however, cells from 
this same culture demonstrate no such suppression of HIV-1 replication. 
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 order to determine whether the antiviral action of TG exosomes was specifically due to 
 prote
combination of trypsin and chymotrypsinogen A for six hours for comparison with untreated 
trypsin alone did not diminish exosome-mediated HIV-1 suppressive activity, suppressing HIV-1 
treatment of exosomes with a combination of trypsin and chymotrypsinogen A abrogated the 
factor mediating the antiviral activity is expressed ectopically on the external surface of the TG 
determine if a protein mediator could be extracted into solution from the exosomes.  Such 
mechanism was involved in inducing HIV-1 suppression and to rule out a possible nonspecific 
lipid inhibition of HIV-1 replication.   
ent was performed by dissolving exosomes in 2:1 
o
exosomes to this treatment, the methanol soluble phase, the chloroform fraction and precipitated 
inhibition of HIV-1 replication.  HIV-1 suppression activity was specifically localized to the 
In
a in factor, separate exosome samples were subjected to treatment with trypsin or a 
exosomes. After protease treatment, exosomes were pelleted by centrifugation, washed and 
resuspended in media and assayed for HIV-1 suppression activity.  Exosome treatment with 
replication by 78% with untreated exosomes suppressing at 83% (Figure 7A). However, 
antiviral activity of the vesicles, displaying only 7% (Figure 7A).  The proteolytic inactivation of 
exosome-mediated HIV-1 suppression activity suggested that the active domain of the putative 
exosomes.  To corroborate this, a series of membrane delipidation experiments was performed to 
experiments were crucial to determining whether the exosome membrane or some lipid-mediated 
 
The first exosome delipidation experim
chlorof rm/methanol, which extracts lipids into the chloroform phase, proteins into the methanol 
phase and as a precipitate at the chloroform-methanol interface (233).  After subjecting TG 
proteins were harvested, lyophilized using a speedvac, resuspended in media and assayed for 
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precipitated proteins and the methanol soluble protein fraction, suppressing HIV-1 replication at 
64% and 56%, respectively (Figure 7B).  However, the extent of antiviral activity was greatly 
diminished in the chloroform fraction, suppressing HIV-1 replication by only 16%, indicating 
that the lipid moiety of exosomes was not involved in mediating HIV-1 suppression (Figure 7B).  
To further confirm this result, a second delipidation experiment was performed, this time using 
cold acetone to deplete exosome lipids.  In this method, lipids are extracted into the organic 
phase producing a protein precipitate. Upon resuspension of the acetone precipitate protein, it 
was observed that not all the protein entered into solution, so a separation of the insoluble 
proteins from those that remained soluble was performed and both protein samples were assayed 
for HIV-1 suppression activity with the insoluble protein fraction assayed as a suspension.  
While a small amount of HIV-1 suppression activity was detected in the insoluble proteins (34% 
compared to 90% for untreated exosomes), most of the acetone-precipitated activity resided in 
the soluble fraction, suppressing HIV-1 replication by 66% (Figure 7C).  Thus, the results of the 
two delipidation experiments corroborated the proteolytic sensitivity of the exosome-localized 
HIV-1 suppressing activity, demonstrating that the antiviral activity was specifically mediated by 
a protein expressed on the external surface of exosomes.  Furthermore, this antiviral factor was 
able to mediate noncytolytic HIV-1 suppression independent of membrane anchoring. 
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igure 7. Exosome suppression of HIV-1 is protein mediated and does not involve exosome 
embrane fusion for activity.  (A) Exosome suppression of HIV-1 is abrogated by 
 
F
m
proteolysis.  (B) HIV-1 suppressive activity is extracted into protein phases after 2:1 
chloroform/methanol delipidation.  (C) Exosome delipidation with cold acetone precipitates 
protein containing HIV-1 suppressive activity. 
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2.4.5 TG exosome suppression of HIV-1 transcription 
With clear evidence of an exosome-localized antiviral activity, the question of whether 
hibition of proviral transcription was 
subsequently explored.  HIV-1 promoter suppression activity was first assessed in an LTR-
activated gene-reporter assay that essentially mimics an acute infection model.  Towards this 
aim, the HeLa-derived TZM-bl cell line that has been genetically engineered for stable 
expression of CD4 and CCR5 was utilized (234).  This cell line contains two stably integrated 
LTR-reporter genes consisting of one construct with the 5’LTR fused to the β-galactosidase gene 
and a second construct with the 5’LTR fused to a luciferase gene.  Expression of the gene-
reporters can be activated in the cell line by HIV-1 infection, transfection of a tat-expressing 
plasmid, or by mitogen stimulation by PMA.  The implementation of this cell line in developing 
an acute HIV-1 LTR suppression assay was based on the methods of Chang et al (172) who 
demonstrated the utility of HeLa cells for assaying HIV-1 transcription suppression activity in 
CD8+ cell culture fluids. These investigators subsequently explored the kinetics of CAF 
induction of LTR promoter inhibition and determined that maximum suppression of the LTR by 
CAF required a pre-incubation time on the order of 16 h before maximum suppression of 
transcription was observed (172).  Therefore, in adapting the TZM-bl cell line for assaying acute 
LTR suppression, a similar kinetic titration was performed by preincubating TZM-bl cells with 
TG exosomes for 3, 6, 12, or 24 hours prior to LTR induction of gene reporter by HIV-1 
inoculation.  After LTR induction, cells were cultured for 24hrs upon which, intracellular β-
galactosidase was assayed.  Maximum suppression of LTR-induced β-galactosidase expression 
only occurred when exosomes were preincubated with TZM-bl cells for at least 6 hours (Figure 
8A). This was in agreement with previous studies demonstrating a delayed induction of 
the TG exosomes specifically suppressed HIV-1 through in
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transcriptional inhibition by CAF (172).  To confirm that the exosome-induced block in β-
galactosidase expression was specifically due to HIV-1 LTR promoter repression, TZM-bl cells 
were pre-incubated with TG exosomes for 12 hours, upon which β-galactosidase expression was 
activated by either virus inoculation, liposome-transfection with the Tat-expressing pSVtat 
plasmid, or mitogen activation with 100 ng/ml PMA.  After 24 hour post-induction incubation of 
TZM-bl cells, potent suppression of the LTR promoter by TG exosomes was observed regardless 
of whether the LTR promoter was virus-, Tat-, or PMA-induced (Figure 8B). 
 
A.       B. 
                           
 
Figure 8.  Exosome-mediated suppression of the HIV-1 LTR promoter. (A) TG exosome 
mediated suppression of TZM-bl cells requires at least a 6 hour preincubation for 
maximum suppression.  (B) Exosomes specifically suppress the HIV-1 LTR promoter 
regardless the method of virus-, tat-, or 
 
was next investigated.  The chronically-infected 8E5 CD4-negative T cell line (244) was utilized 
as a target to assay exosome-mediated HIV-1 transcriptional repression.  The 8E5 cells contain a 
PMA- induced LTR-gene reporter expression. 
 
 Since the LTR gene-reporter assay mimicked an acute infection model, the question of 
whether TG exosomes could also suppress HIV-1 transcription in a chronic model of infection 
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single full-length copy of an integrated HIV-1 LAV genome with a null mutation in its reverse 
transcriptase that results in the production of non-infectious virions (244).  Since no cell-to-cell 
transmission of virus occurs, any suppression of HIV-1 in the 8E5 cell line is specifically 
directed at a post-integration step of the virus life cycle.  8E5 cells were therefore cultured in the 
absence or presence of TG exosomes in a time course experiment. Total HIV-1 RNA copies per 
1000 cells were measured every 5-7 days and cells were replenished at each time point with 
media alone or media supplemented with TG exosomes in addition to adjusting cell 
concentrations to maintain healthy cell growth.  After measuring an initial transient spike in 
HIV-1 RNA at day 5 in 8E5 cells cultured in the presence of exosomes, a dramatic and sustained 
exosome-induced reduction of intracellular HIV-1 transcripts was observed with no such 
reduction for controls with a near 2 log10 reduction in viral between day 5 and the last timepoint 
of the experiment (Figure 9).   
 
                             
Figure 9.  Inhibition of HIV-1 transcription in 8E5 cells by exosomes (black triangles) 
compared to controls (white diamonds). 
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The reduction of HIV-1 RNA only after Day 5 for 8E5 cells cultured in the presence of 
exosomes was consistent with a delayed kinetics of LTR promoter repression demonstrated in 
the TZM-bl cell line (Figure 8A) and by others for CAF (172).  The potent HIV-1 transcription 
suppression in acute and chronic models clearly defines the mechanism TG exosomes employ to 
suppress HIV-1 replication, exhibiting the key hallmark defining CD8+ cell- and CAF- mediated 
HIV-1 transcriptional suppression.   
 
Experimental results thus far appeared to identify secreted TG exosomes with the key 
hallmar
ed HIV-1 suppressive factors also being secreted by CD4+ 
 cells (231).  The possibility that exosomes from other cell lineages might also suppress HIV-1 
transcription was therefore explored.  An assessment of the antiviral activity of exosomes from 
primary CD4+ T cells in comparison to TG exosomes was undertaken.  Primary CD4+ T cells 
were c
2.4.6 Cell specificity of exosome-mediated suppression of HIV-1 transcription 
ks defining noncytolytic CD8+ T cell suppression of HIV-1, namely the suppression of 
R5 and X4 HIV-1 isolates and specific inhibition of the viral LTR promoter in acute and chronic 
models of infection.  One question we wished to determine was whether these antiviral exosomes 
were specific only to the CD8+ T cell lineage.  Previous studies have noted that cell-mediated 
noncytolytic HIV-1 suppression appears to be an exclusive function of CD8+ T cells (245). 
However, recent reports have describ
T
ollected from a seronegative donor and activated with OKT3 anti-CD3 antibody and 
recombinant IL-2 for 7 days.  At Day 0 of the CD4+ T cell culture, an independent parallel TG 
cell culture was split into fresh media.  At day 7, exosomes were harvested from both TG and 
CD4+ T cell culture fluids and stored at -70 ºC cells while TG and CD4+ T cells were recultured 
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in media supplemented with IL-2 for another seven days.  At day 14, exosomes were harvested 
from TG and CD4+ T cell cultures.  Both day 7 and day 14 exosomes from each cell type were 
assayed for HIV-1 transcription suppression activity using the TZM-bl cell-based acute LTR 
promoter suppression assay.  For exosomes harvested at day 7, TG exosomes suppressed the 
LTR to a 2.3-fold higher level than CD4+ cell derived exosomes (Figure 10A, Black Bars).  
However, at day 14, CD4+ T cell secreted-exosomes were now found to suppress the LTR 
promoter by 90% compared to CD4+ T cell exosomes from day 7 which suppressed LTR 
transcription by only 34% (Figure 10A).  These results indicated that exosome-mediated 
suppression of HIV-1 transcription was not necessarily exclusive to CD8+ T cells.  A 
verification of this result was made by analyzing exosomes from several distinct cell lines.  
Large cultures of H9, a CD4+ T cell line; Raji, an EBV-transformed B cell line; U937, a 
monocyte cell line; and HeLa cells were made. Exosomes were purified from the culture fluids 
of these cell lines and assayed for HIV-1 transcription suppression.  In corroboration with the 
previous result with primary CD4+ T cells, potent exosome-mediated LTR suppression activity 
was observed from H9 cell-secreted exosomes, suppressing the HIV-1 promoter activity by 87% 
(Figure 10B). A moderate amount of LTR suppression activity was also detected in Raji 
exosomes (51% LTR transcription suppression) with no LTR suppression was found in U937 
exosomes, and only a small amount found for HeLa exosomes (22% LTR transcription 
suppression).  These results demonstrate that exosome-mediated HIV-1 suppressive activity is 
not the exclusive domain of CD8+ T cells and suggest instead that the exosome-mediated 
antiviral activity is largely restricted to cells of the lymphocyte lineage, particularly T cells as 
only moderate antiviral activity was found in exosomes from the Raji B cell line.  These results 
corroborate more recent findings of a CD4+ T cell secreted antiviral factor (231). 
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        A.          B.  
           
 
Figure 10.  HIV-1 suppression activity of exosomes from other cell types. (A) Exosomes 
from activated primary CD4+ T cells display low HIV-1 transcription suppression activity 
at Day 7, but very high amounts of activity at Day 14.  (B) HIV-1 transcription suppression 
activity by exosomes prepared from H9,  Raji,  U937,  and HeLa cell culture fluids. 
 
2.4.7 Contribution of exosomes to secreted CAF activity 
Since TG exosomes represent a CD8+ cell-secreted antiviral factor with potent HIV-1 
transcription inhibition activity, an investigation into the contribution of exosomes towards HIV-
1 transcription suppression activity in CD8+ cell culture fluids was undertaken.  Such an 
investigation was important to verify whether the secreted antiviral activity was due to CD8+ 
cell-secreted exosomes or to a soluble protein factor, as has been previously postulated (245).  A 
starting point for this enquiry was taken from the original fractionation of membrane vesicles 
from TG culture fluids where it was observed that only moderate amounts of antiviral activity in 
60,000xg membrane pellets compared to 6000xg and 15000xg pellets (Figure 3A).  This would 
indicate that centrifugation at 15000xg depletes a majority of exosomes from cell culture 
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supernatant.  The question consequently arises as to whether or not LTR suppression activity 
also diminishes in CD8+ cell culture supernatant after exosome-depletion.  If a secreted factor is 
purely membrane bound, then reduction of the vesicles expressing the factor should be 
coincident with a reduction of antiviral activity.  However, if vesicles are depleted but a 
substantial portion of the activity still remains, it would indicate the presence of a soluble 
membrane-free factor mediating the same activity.  In an attempt to answer this question, five 
independent TG culture fluid samples were depleted by serial centrifugation at 300xg, followed 
by 800xg centrifugation, with a third centrifugation at 6000xg to deplete cells and large debris 
from the culture fluid samples. An aliquot of 6000xg-depleted supernatant was extracted and the 
 culture 
samples demonstrated large reductions in HIV-1 transcription suppression activity coincident 
11A, 11B, and 11C).  Two of the 
five TG culture sam
activity after exosome depletion (Figures 11D and 11E).  The percentage reduction of HIV-1 
2%, and 0% reduction in LTR promoter activity (Figure 11F). These results indicate that HIV-1 
transcription suppression activity in cell-free TG culture fluid can be mediated by either 
incomplete reduction of LTR transcription suppression was found after 15000xg centrifugation 
 
remaining fluid was centrifuged at 15000xg to deplete exosomes. Both 6000xg-depleted and 
15000xg-depleted supernatant were assayed for HIV-1 transcription suppression activity using 
the TZM-bl cell-based LTR promoter suppression assay. Only three of the five TG
with 15000xg centrifugation depletion of exosomes (Figures 
ples displayed no such significant reduction in LTR promoter suppression 
transcription activity after 15000xg exosome depletion spanned a spectrum of 97%, 65%, 62%, 
exosomes or a soluble factor, or in the case of two of the five samples analyzed where 
(Figures 11B and 11C), a combination of both. 
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Figure 11. Analysis of physiologically secreted HIV-1 transcription suppression activity in 
demonstrated reduction of HIV-1 transcription suppression activity after 15000xg exosome 
after exosome depletion (D-E).  Comparison of percentage reduction in LTR suppression 
TG culture supernatant sample correspond respectively to panels (A) through (E) for this 
er
-d
n 
o
m
 
culture supernatant taken from five independent TG cultures.  Three of the five samples 
depletion (A-C).  Two of the five samples displayed no such reduction in antiviral activity 
activity after exosome depletion for the five samples (F).  In panel (F), the labels A-E for 
dataset.   
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 2.5 DISCUSSION 
The current study into the possible existence of membrane determinants mediating 
noncytolytic CD8+ T cell suppression of HIV-1 has demonstrated the existence of a membrane-
bound factor secreted through exosomes which specifically inhibits transcription of HIV-1 from
e proviral LTR promoter.  A critical result of this investigation was the finding that TG cell-
ete exoso es c  supp onic and acute models of 
infection. TG exosome-mediated inhibition of HIV-1 transcription in the chronically infected 
8E5 cell line is consistent with previous observations of CD8+ T cells suppression of HIV-1 in 
endogenously infected heterologous CD4+ cells (173).  Additionally, the methodology used for 
demonstrating transcriptional suppression of the LTR promoter in TZM-bl cells indicates that 
exosomes can actually induce uninfected cells into suppressing the viral promoter before 
activation by viral infection, tat-expression, or mitogen induction.  This may highlight a possible
R5 and X4 HIV-1 isolates. It also confirms the involvement of only host cell proteins in 
mediating HIV-1 transcriptional suppression, a result previously observed for secreted CAF 
activity (172).   
 
 
th
secr d m an ress HIV-1 transcription in both chr
 
role CD8+ T cell secreted exosomes may play in inducing what other researchers have noted as 
transcriptional latency or latent infection in CD4+ T cells (191).  The transcriptional suppression 
of PMA-induced LTR promoter observed in this study clearly demonstrates the non-antigenic 
requirement of this antiviral activity and easily explains TG exosome-mediated suppression of 
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TG-secreted exosomes appear to identify strongly with key hallmarks defining CAF and 
the CD8+ T cell-mediated noncytolytic HIV-1 suppressive activity. However, some peculiar 
es secreted by primary CD4+ T cells and the H9 
CD4+ T cell line were also observed to potently suppress the LTR promoter to a degree 
compar
derived from the limiting membranes of late endosomes and as such are likely 
subject to the same membrane-restricted compartmentalizations that other exosome proteins, 
results were observed in this study.  Exosom
able to TG exosomes, with the Raji B cell line also displaying significant amounts of 
LTR suppression activity. This suggests that the exosome-localized factor mediating HIV-1 
transcriptional suppression is not exclusively expressed by CD8+ T cells. This result should 
come as no surprise in light of recent reports demonstrating the secretion of noncytolytic HIV-1 
suppression activity from CD4+ T cells (231).  These results disagree strongly, therefore, with 
previously held assertions by other investigators that the antiviral factor mediating noncytolytic 
HIV-1 suppression is the exclusive domain of CD8+ T cells (245).  Such conclusions of 
specificity have been largely made based on cell-mediated assays (167).  The investigation 
performed here represented a more involved attempt to determine the possible role membrane 
determinants play in mediating potent suppression of HIV-1.  The finding of a membrane-bound 
factor mediating potent HIV-1 suppression represents a new paradigm for elucidating the role 
cell contact-dependent determinants play in mediating noncytolytic HIV-1 suppression by CD8+ 
T cells.   
 
In this respect exosome-mediated HIV-1 transcriptional repression may be the key to 
understanding how noncytolytic HIV-1 suppression activity is regulated within CD8+ T cells 
and why a dissociation exists between secreted- and cell-mediated antiviral activities.  Exosomes 
are specifically 
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such as
on is highlighted further by an additional curious result.  The analysis of LTR 
promoter suppression activity in TG culture supernatant samples before and after exosome 
depleti
 MHC class II and tetraspanins like CD9, CD63, and CD81 are subject to.  This suggests 
a level of complexity in CD8+ T cell manifestation of the HIV-1 suppression activity beyond 
simple gene expression of an antiviral factor. This complexity is further evidenced by 
observations in this study of CD4+ cell-secreted exosome suppression of HIV-1 and the 
disconcordance between cell- and exosome-mediated mechanisms of HIV-1 suppression.  
Consequently, efforts to elucidate the molecular identity of the factor(s) mediating the antiviral 
activity based only on the premise of differential gene product expression, such as the microarray 
analysis of HIV-1 suppression and non-suppressing CD8+ T cells recently reported by Diaz et al 
(235), are unlikely to yield conclusive results as to the antiviral factor’s molecular identity.  As a 
corollary, how the factor mediating HIV-1 transcriptional suppression traffics intracellularly, 
particularly in the context of the tetraspanin proteins it is found to colocolize with on exosomes, 
may be the key to understanding why specificity of the antiviral effector function to CD8+ T 
cells might be found at a cellular level, but extracellular secretion of a factor mediating the same 
activity can be observed in other cell lineages. 
 
Such mechanistic complexities involved in CD8+ T cell repression of HIV-1 
transcripti
on suggest that secreted CAF activity can be mediated by a combination of both secreted 
exosomes and a soluble molecule. The demonstration of membrane-bound and membrane-free 
mediators of an HIV-1 transcription suppression activity represents an additional intricacy to the 
dissociation found between cell- and secreted-factor mediated noncytolytic antiviral activity by 
CD8+ T cells (183,185).  Since both exosomes and an apparent soluble factor mediate their 
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antiviral action at the level of inhibiting HIV-1 transcription, an argument could be made that the 
exosome-localized antiviral protein and the soluble antiviral factor are either molecularly related 
or share a common target to effect repression of the LTR promoter in CD4+ cells.  If the soluble 
and membrane-bound antiviral factors are indeed molecularly related, an inverse relationship 
between exosome-mediated and exosome-free mediators of the antiviral activity in CD8+ cell 
culture fluids might be detected in a more thorough analysis of the activity.  If such a result were 
found, it would suggest that the membrane-bound HIV-1 suppressive factor serves as a precursor 
for the formation of a membrane-free soluble form of the antiviral activity.  Such a postulate 
would be consistent with the slight decreases in antiviral activity observed after sodium 
carbonate treatment of raw TG membranes, as this is consistent with the dislodging of a soluble 
mediator from a membrane-bound precursor.   The precise relationship between an exosome-
localized HIV-1 suppressing factor and an apparent soluble mediator is an area of active research 
at the present moment.  Elucidation of the molecular factor(s) mediating either means of HIV-1 
suppression would ultimately determine the overall mechanistic nature of noncytolytic HIV-1 
suppression displayed by CD8+ T cells.  For such an undertaking, CD8+ cell-secreted exosomes 
represent a potentially valuable source for purification of this elusive antiviral activity.  The 
discovery of a novel membrane-bound factor inhibiting HIV-1 transcription and secreted through 
exosomes provides a new frame of thought for understanding, and possibly solving, the enigma 
of CD8+ T cell noncytolytic suppression of HIV-1. 
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 3.1 ABSTRACT 
CD8+ T cells express a factor capable of suppressing of HIV-1 transcription in CD4+ 
cells.  This CD8+ cell antiviral factor (CAF) has been shown to be secreted, but does not identify 
with any known lymphokine.  In the previous c es 
secreted by a CD8+ T cell line, TG, were le to mediate potent suppression of HIV-1 
transcription.  In the previous investigation, evidence was uncovered that secreted CAF activity 
dua ng 
HIV-1 transcriptional suppression has a mechanistic relationship to the soluble protein mediating 
the same antiviral action.  An investigation was ze the biophysical nature 
of the membrane-localized and membrane-free HIV-1 transcription suppression activities.  
Through a series of biochemi as uncovered indicating that 
a soluble antiviral mediator is derived from a membrane-bound precursor on the exosomes.  
F  
enzymatic activ  activity into a 
soluble form.  The results of this study mechanistically reconcile exosome- and soluble protein-
mediated suppression of HIV-1 transcription observed in CD8+ cell culture fluids and strongly 
suggests CAF secretion is an exosome-driven phenomenon. 
 
hapter of study, it was discovered that exosom
ab
could be mediated by secreted exosomes and by some soluble CD8+ cell secreted-factor.  This 
l nature to CAF activity led to the speculation that the exosome-localized factor mediati
undertaken to characteri
cal and proteomic analyses, evidence w
urthermore, evidence was uncovered suggesting a possible CD8+ cell exosome-specific
ity functioning in the conversion of the membrane-bound antiviral
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3.2 INTRODUCTION 
The molecular identification of the factor(s) mediating CD8+ T cell noncytolytic 
res  has been an enigma in the field of AIDS research.  Elucidating the 
antiviral activity is of much interest due to its potent inhibition of genetically divergent HIV-1 
isolates and its nontoxic action via inhibition or proviral transcription (172,186-190).  While the 
involvement of a secreted CD8+ antiviral factor, termed CAF, has been noted in several 
investigations (172,181,182), more recent studies have revealed a CD8+ cell expressed integral 
membrane factor with potent HIV-1 transcriptional suppression activity (Chapter 2, Tumne et 
al).  In this previous investigation, the secretion of this antiviral activity in the form of spherical 
membrane-limited 30-100nm vesicles termed exosomes was demonstrated along with evidence 
demonstrating that exosomes were a functional component of secreted CAF activity.  Initial 
biophysical analysis had revealed the exosome-localized factor mediating the antiretroviral 
activity to be a protein expressed on the external surface of the CD8+ cell-secreted nanovesicles.  
In the analysis of CAF activity in CD8+ cell culture fluids, instances were observed where 
exosomes constituted almost all of the CAF activity, while in other CD8+ cell culture fluid 
samples, CAF activity appeared mediated almost exclusively by a soluble factor.  Since the 
antiviral action of the membrane-bound and membrane-free mediators specifically inhibited LTR 
promoter activity, it raised speculation that this apparent dichotomy may due to the soluble 
mediator deriving itself from the membrane-bound precursor also mediating the same activity. 
 
 where it was observed that sodium 
arbonate treatment appeared to remove a small fraction of the activity from purified CD8+ cell 
membrane.  However, the majority of the antiviral activity appeared to be tightly associated to 
supp sion of HIV-1
Initial biochemical data was consistent with this idea
c
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the m mbrane, indicating foe r the first time the existence of an integral membrane factor with 
noncytolytic HIV-1 suppression activity. Proteolytic analysis had demonstrated the membrane-
bound factor to be expressed on the external surface of exosomes, with delipidation experiments 
tethering.  To reconcile the combined results of the previous study, a hypothesis was raised that 
to this postulate is an inferred existence of a putative protease or enzymatic activity to release a 
catalytically active antiviral molecule from its membrane-anchored precursor.  There are, 
factor concurrent with one that is also membrane-bound.  For instance, if the two factors are 
action would not be required for the appearance of soluble and integral membrane proteins.  
Another possibility might also be that the membrane-bound factor and soluble protein mediator 
expression of the two factors would be expected to be independent of each other and an inverse 
the membrane-bound and soluble mediators of secreted LTR suppression activity do have a 
exosome-mediated LTR suppression activity with an inverse correlation between exosome-
localized and soluble protein-mediated antiviral activity; and (ii) Evidence supporting a catalytic 
activity coincident with the release of a soluble LTR suppressing factor mediator. 
demonstrating that the protein factor could exert its antiviral action independently of its lipid 
the HIV-1 suppressive factor might exist as a cleavable integral membrane protein.  A corollary 
however, alternative models that may also explain the appearance of a soluble antiviral protein 
expressed as isoforms through alternative splicing of a shared mRNA sequence, an enzymatic 
are two distinct gene products mediating the same action.  If this is the case, then cellular 
correlation between soluble and membrane bound activities would not be expected.  Therefore, if 
common precursor protein, two phenomena should be readily detected:  (i) Fluctuations in 
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An investigation into the biophysical nature of the soluble / membrane-bound dichotomy 
of this antiviral activity was therefore undertaken.  While the focus of the previous investigation 
in Chapter 2 was to determine conclusively the existence of a membrane bound HIV-1 
transcription suppression activity and its physiological nature, attention in this study focused on 
defining the mechanistic relationship between the exosome-mediated LTR suppressing activity 
and its appearance in a soluble form.  In doing so, evidence was uncovered for the soluble LTR 
suppressing factor being directly produced from a membrane-bound precursor also exhibiting the 
same activity.  These results strongly suggest that secreted CAF activity is largely exosome 
driven and argue against a multifactorial cytokine release hypothesis that has previously been 
proposed for CAF activity (201).  The novel experimental techniques and analytical methods 
performed in this study can ultimately be applied towards conclusive identification of the elusive 
molecular factor(s) mediating noncytolytic HIV-1 suppression. 
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 3.3 MATERIALS AND METHODS 
 is used throughout the study as 
this gene-reporter assay has proven to be a very sensitive and reproducible assay for the 
evaluation of biochemically extracted samples mediating HIV-1 transcription inhibition.    
 
Exosome Preparation 
 Exosomes were prepared essentially as described in Chapter 2 by serial centrifugation of 
cell culture supernatant followed by sucrose gradient fractionation of the 15,000xg membrane 
pellet. In some experiments, after the final wash and pelleting of exosomes from the 60% sucrose 
density gradient fraction, exosomes were resuspended 0.1 M sodium carbonate instead of HBSS.  
 
About methods used in this section of the study 
 As the current study presented in this chapter is a direct continuation of results gleaned 
from the last chapter, this following section of study borrows heavily the methods used in 
Chapter 2.  As such, the reader may reference experiments described in this Chapter 3 with some 
of the methods used in Chapter 2.  In particular, TG cell cultures, exosome preparations, and the 
acute LTR suppression assay using the TZM-bl gene-reporter cell line are used in this section of 
the study as essentially described in Chapter 2, with some minor modifications where noted in 
this Chapter. The TZM-bl acute HIV-1 LTR suppression assay
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Quantitative Exosome Assay 
 The method of Clayton et al (232) was adapted to develop a quantitative assay for 
measurement of relative exosome concentrations between samples under nonsaturating 
conditions of exosome bead-capture. Immunomagnetic beads coated with antibodies specific for 
ashed and resuspended at a concentration of 
x106 b
xtraction of Peripheral Membrane proteins from the exosomes 
pelleted by microfuge centrifugation at 20,000xg for 30 minutes. 
elleted by microfuge centrifugation to extract supernatant containing solublized proteins.  
Dialysis and concentration of soluble proteins after salt extractions was performed by three 
successive rounds of washing and microfiltration using a 5 kDa cutoff microfilter cartridge 
MHC Class II molecules (Dynal, Norway), were w
5 eads per 1 ml in 2% FCS/PBS. A volume of 200 ul containing 106 beads was mixed with 
50 ul of sample containing exosomes and incubated on a rotator (Dynal, Norway) at 4ºC for 12 h 
at 35 rotations per minute. After bead-exosome incubation, beads were washed twice with 2% 
FCS/PBS and stained with anti-CD63 PE-labeled or isotype control monoclonal IgG1 antibody 
and analyzed by flow cytometry, as described in Chapter 2. Under conditions of non-saturating 
exosome-bead binding, the extent of CD63-dependent fluorescence shift relative to isotype 
antibody controls is directly proportional to the exosome concentration of the sample (232).  A 
proof-of-principle for this technique is described in the results of this investigation 
 
E
 Exosomes were 
Exosomes were then resuspended in a variety of solutions for extraction of peripheral membrane 
proteins at 4°C. These treatments included 1M NaCl for 30 minutes, HBSS for 30 minutes and 
for storage of exosomes at 4°C or -70°C, 0.1 M sodium carbonate, pH 11.5 for 30 minutes, 
deionized double distilled H2O (dI-ddH2O) for 16-24 hrs. Upon treatment, exosomes were re-
p
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(Millipore, US).  The final 5 kDa microfilter dialyzed concentrate was resuspended into media 
 sample was 
ophilized for MALDI-TOF-MS analysis.  In preparation of MALDI-TOF-MS samples, 
0.3% tricitric acid / 50% 
etyln
for assaying HIV-1 suppression activity at a volume equivalent to the original exosome 
preparation the extract was derived from.  Dialysis using the 5 kDa cutoff microfilter was found 
to fully retain LTR suppression activity (data not shown).  
 
MALDI-TOF-MS analysis of TG and H9 catalytically released proteins 
 TG and H9 secreted exosomes were purified, assessed for protein concentration using a 
BioRad assay, treated with 0.1 M sodium carbonate pH 11.5 to remove peripheral proteins from 
the exosomes.  After a 30 minute treatment at 4ºC, the membrane fraction was separated from 
the supernatant by centrifugation at 20,000xg.  The resulting exosome membrane pellet was 
rinsed three times with dI-ddH2O to remove residual salt before resuspending 
 the pellet in dI-ddH2O.  Aliquots of the dI-ddH2O extracted proteins were assayed for HIV-1 
suppression activity. A second aliquot of each dI-ddH2O extracted exosome
ly
lyophilized samples were resuspended in 3 ul of a solution of 
ac itrile and then mixed with 3 ul of α-cyano-4-hydroxycinnamic acid. Aliquots of 1.5 ul 
were spotted on a stainless steel mass spectrometer plate and dried at 40°C. The matrix-
embedded samples were then analyzed by MALDI-TOF-MS on a Voyager DE-PRO Mass 
Spectrometer (Applied Biosystems, US). 
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3.4 RESULTS 
 
In the previous study of CD8+ cell culture fluids, se
3.4.1 Variability in exosome-mediated HIV-1 LTR promoter suppression activity 
creted CAF suppression of the HIV-1 
TR promoter was found to be mediated by a combination of exosomes and some soluble factor 
due to exosomes or 
r.  A time-course 
L
(Chapter 2, Figure 11).  The extent to which secreted CAF activity was 
soluble factor suggested an inverse correlation between the two mediators of HIV-1 transcription 
suppression.  It was not known at the time whether the LTR suppression activity fluctuated with 
respect to its exosome localization in the TG cell line.  If it did, exosome samples displaying 
divergent degrees of antiviral activity would provide an important starting point for molecular 
dissection of the protein factor mediating suppression of the HIV-1 promote
analysis of the exosome-mediated antiviral activity was performed for two independent TG 
cultures that were at late stages of culture.  Exosome purifications were performed at four 
independent time points for each culture and exosome samples were standardized by protein 
content. The HIV-1 LTR suppression activity of each purified exosome sample was assayed 
using the TZM-bl cell line-based acute LTR suppression assay described in the previous chapter 
of study.  In the panel of samples analyzed, two instances over a time course from day 52 to day 
100 were found where exosome-mediated LTR suppression activity fluctuated in both TG 
cultures (Figure 12A and 12B). 
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  A.           B. 
               
Figure 12.  Measurement of exosome-mediated HIV-1 LTR suppression activity over a time 
Exosomes from a TG cell culture maintained at saturating plateau conditions. 
 
The analysis indicated that fluctuations in exosome-mediated LTR suppression do occur 
in the TG cell line.  The possibility that this variability was due to differences in exosome 
concentration between the samples was addressed.  An exosome titration assay based on the 
quantitative immunomagnetic bead-capture method of Clayton et al (232) was employed to 
determine the validity of normalizing independent exosome samples by protein concentration.  
The quantitative detection of exosomes using anti-MHC Class II antibody-coated beads is based 
on the principal that under cond
course study.  (A) Exosomes from a TG cell culture maintained in log-phase growth.  (B) 
 
itions of unsaturated bead capture of exosomes, flow cytometric 
measurement of exosome markers produces a fluorescence shift relative to isotype control that is 
directly proportional to concentration of exosomes present during bead binding (232).  The 
utility of this assay was tested in a titration experiment on three exosome samples purified from 
three independent TG cell cultures. A two-fold dilution series of each of the three independent 
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samples was made from 80 µg/ml to 10 µg/ml.  Applying the quantitative exosome capture 
assay, a striking linear correlation was found between exosome protein concentration and CD63 
fluorescence shift (Figure 13), demonstrating utility of protein concentration for standardizing 
exosome samples. The concordance between the three independent exosome samples indicated a 
high degree of reproducibility for the quantitative exosome capture assay.   
 
 
Figure 13.  Demonstration of linearity in the bead-capture exosome quantitative assay on 
dilution series of three independent TG exosome samples.   
 
 
 
The exosome quantitative assay was next used to analyze three exosome samples from 
the time-course analysis in Figure 12 that displayed high, medium and low HIV-1 LTR 
suppression activities (Figure 14A).  Applying the quantitative exosome assay, the three samples 
with divergent antiviral activities were found to contain equivalent amounts of exosomes as 
indicated by similar CD63 dependent shifts (Figure 14B).  This demonstrated that the fluctuation 
of exosome-mediated HIV-1 LTR suppression activity observed in TG cell cultures was 
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specifically due to the variable presence of the activity on the exosomes themselves and not to 
differences in exosome concentration or method of standardization.  
 A.       B. 
              
Figure 14.  Comparison of LTR suppression activity and relative exosome concentrations in 
three exosome samples (i), (ii), and (iii).  (A) LTR suppression activity of three exosome 
samples (i), (ii), and (iii) as standardized by protein content.  (B) Measurement of relative 
exosome concentrations, as denoted by CD63 positive fluorescence shift, of the three same 
exosome samples (i), (ii), and (iii), standardized by protein content. 
 
alizing to exosomes, the possible 
lationship of TG exosome-mediated antiviral activity with antiviral activity in exosome-
deplete
 
After determining the specific variability of a factor loc
re
d culture supernatant was next explored.  Upon analysis of several independent samples, 
instances were observed where (i) LTR suppression activity was found exclusively in the 
exosomes (Figure 15A); (ii) LTR suppression activity was localized to both supernatant and 
exosomes (Figure 15B); and (iii) LTR suppression activity was found only in the supernatant and 
not exosomes (Figure 15C).  These results further verified the observed fluctuations in exosome-
mediated antiviral activity do occur and appeared to portray a pattern of inverse association 
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between exosome-localized LTR suppression activity and the appearance of a soluble mediator 
in exosome-depleted TG culture fluids. 
A.          B.     
                  
 
 
 
C. 
 
 
 
supernatants to the purified exosomes depleted from them.  (A) LTR suppression activity is 
exosomes and exosome-depleted supernatant.  (C) LTR suppression activity is only found 
Figure 15.  Comparison of LTR suppression activity in exosome-depleted TG culture 
found exclusively in TG exosomes.  (B) LTR suppression activity is found in both TG 
in exosome-depleted culture supernatants and not in the exosomes. 
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 3.4.2 Nature of the LTR suppressing factor’s localization to TG exosomes 
The apparent fluctuation of the LTR suppressing activity between an exosome-localized 
and soluble form prompted a more precise evaluation concerning the nature of the LTR-
suppressive activity’s localization to the exosome membrane.  If the HIV-1 transcription 
suppressing factor was a cleavable integral membrane precursor, then the soluble form of the 
activity might still be localized as a loosely bound peripheral membrane protein on the exosome 
surface.  If this represented the means by which a soluble factor appeared in TG culture fluids, 
then the extent to which HIV-1 transcrip ression activity is membrane-bound shou
orrelate inversely with the appearance of a soluble mediator on the exosomes and in exosome-
leted culture supernatant.  To explore this possibility, a biochemical analysis was performed 
on two independent exosome samples that had been purified and stored at -70ºC from a previous 
study in which one culture displayed considerable LTR suppression activity in exosome-depleted 
culture fluid (Figure 11E) with the second culture displaying no such activity from a soluble 
protein mediator in exosome-depleted culture fluid (Figure 11A).  The two exosomes samples 
were subjected to a variety of salt treatments to quantify the extent of soluble LTR suppression 
activity to that which remained membrane-bound after extraction. 
 
In the first exosome sample from which significant LTR suppressing activity was found 
were stored in HBSS overnight with an aliquot of exosome-depleted culture supernatant stored at 
tion supp ld 
c
dep
in exosome-depleted culture fluid (Figure 11E), the exosomes were subjected to a series of 
soluble extractions as outlined in Figure 16.  After purification from cell culture fluid, exosomes 
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-70ºC prior to their analysis. Upon thawing, an untreated aliquot of the exosome suspension was 
saved as a control before the remaining suspension was centrifuged to pellet the exosomes and 
extract the storage buffer supernatant for analysis.  The exosome pellet was treated with 0.1 M 
sodium carbonate, pH 11.5 to remove all remaining peripheral proteins. After treatment, 
exosomes were pelleted and supernatant of the sodium carbonate extract and the exosome 
storage buffer supernatant were separately dialyzed into media.  The sodium carbonate-treated 
exosome pellet was washed and resuspended into media.  LTR suppression activity was assayed 
for each of the fractions collected.  No HIV-1 promoter inhibition activity was found in the 
exosomes after sodium carbonate treatment (Figure 17).  The LTR suppression activity was only 
found in dialyzed sodium carbonate fractions and storage buffer supernatant in addition to its 
appearance in culture supernatant after exosome purification.  In addition, The LTR suppression 
activity was considerably higher in exosome-depleted supernatant than that found in the purified 
exosomes (43% and 23% LTR suppression activity, respectively). In this particular exosome 
sample, the activity was found to be completely localized to exosomes as a loosely bound 
peripheral protein.   
 
 
 
 
 
 
 
 
 
 
 
Figure 16.  Schematic for the analysis of exosomes from a TG culture in which the culture 
supernatant displayed considerable antiviral activity after exosome depletion.   
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Figure 17.  LTR suppression in fractions harvested from the exosome sample purified from 
the TG culture described in Figure 11E.  TG exosome-depleted supernatant activity was 
considerably higher than untreated exosomes.  Untreated exosomes also contained 
equivalent LTR suppressing activity that was eluted into storage buffer and the dialyzed 
sodium carbonate supernatant. 
 
 
A similar analysis was next performed on a second exosome sample that was previously 
prepared from a TG cell culture in which no LTR suppressing activity could be found in 
exosome-depleted culture fluid (Figure 11A).  The experimental schema for the second analysis 
is outlined in Figure 18.  This second treatment consisted of a much more rigorous analysis to 
ensure that salt extraction of peripheral proteins was complete and exhaustive.  This included 
subjecting exosome aliquots to 1M sodium chloride extraction as well as performing two serial 
sodium carbonate extractions on an exosome sample to ensure thorough removal of soluble 
proteins (Figure 18).  After performing the various treatments outlined, the various soluble and 
the exosome fractions were assayed for LTR suppression activity. 
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Figure 18.  Schematic outline of
soluble
 activity of resuspended post-
treatment exosome pellet fractions, in contras to the previous exosome sample, this second 
 the subsequent elaborate analysis of exosome-extracted 
 fractions.  Exosome extractions performed included buffer,  sodium chloride, 
sodium carbonate, and re-treatment with sodium carbonate. 
 
 
In agreement with the previous analysis, HIV-1 LTR promoter suppression activity was 
eluted from this second independent exosome sample by sodium chloride treatment and sodium 
carbonate treatments in addition to its elution into HBSS that was used as a storage buffer for 
exosomes (Figure 19A).  Very surprisingly, however, HIV-1 LTR suppression activity was 
eluted into solution after two successive rounds of sodium carbonate treatment of exosomes 
(Figure 19A, last bar from the left).  Upon assaying the suppression
t 
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exosome sample was actually found to retain membrane-localized LTR suppression activity even 
after two successive rounds of sodium carbonate treatment (Figure 19B).  In contrast to the 
previous exosome sample (Figure 17), a tight association of the peripheral membrane protein 
mediating the LTR suppression activity to exosome membranes was found in this second sample.  
Such results are inconsistent with the LTR suppressing factor associating to exosomes as a 
purely peripheral protein. 
 
 A.         B. 
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Figure 19.  Sodium chloride and sodium carbonate extractions of a second TG exosomes 
sample
depleted TG culture fluids, exosome storage buffer, sodium chloride, and sodium carbonate 
chloride treatment, or 1X or 2X sodium carbonate treatments. 
 
The extraction of the LTR suppressive activity from exosomes into solution with the 
activity still also retained in an exosome-bound form appeared to hint at a possible ongoing 
conversion of a membrane-bound molecule into a soluble form.   To determine whether such a 
model for the exosome-bound LTR suppressing factor was valid, exosomes from two 
 
. (A) Soluble fractions from 6000xg- depleted TG culture fluid, 15000xg exosome-
1st and 2nd treatments.  (B) Untreated exosomes or pelleted exosomes after sodium 
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independent TG cell cultures were purified, resuspended in deionized double distilled water (dI-
ddH2O) and stored for 24 h at 4 ºC.  Exosomes were next pelleted by centrifugation and the 
supernatant was extracted.  Pelleted exosome were subjected to sodium carbonate treatment to 
deplete remaining peripheral membrane proteins followed by dialysis of the extracted sodium 
carbonate supernatant into buffer.  The sodium carbonate-treated exosomes were then 
resuspended in dI-ddH2O for a second 24 h extraction at 4 ºC.  After assaying the various 
fractions for HIV-1 LTR suppression activity, a high amount of antiviral activity was found 
luted in the dI-ddH2O fractions even after sodium carbonate removal of peripheral protein 
(Figure 20).  That the last extraction with dI-ddH2O contained approximately 2-fold greater 
antiviral activity than after the preceding sodium carbonate removal of peripheral proteins, a 
result consistent with catalytic conversion of a membrane-bound molecule into a soluble form.  
 
 
 
e
 
 
 
exosomes were resuspended in pure water and subjected to a three step extraction of 
 
 
Figure 20.  Experimental verification of a possible catalytically released factor.  Purified 
soluble protein.  
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3.4.3 Comparison of soluble and membrane-bound LTR suppression activity between TG 
and H9 exosomes 
extended to determine if the same phenomenon held for exosomes from the H9 cell line, as these 
CD4+ cell-secreted exosomes also display potent inhibition of HIV-1 transcription (Chapter 2, 
for overnight extraction of soluble proteins at 4°C. Exosomes were then pelleted to harvest the 
water-dialyzed sodium carbonate supernatant and resuspended exosome membrane pellets were 
prepared.  The dI-ddH O and sodium carbonate supernatant and exosome pellet fractions were 
The biophysical analysis performed with dI-ddH2O and sodium carbonate extractions was 
Figure 10).  Exosomes from H9 and TG cell cultures were purified and resuspended in dI-ddH2O 
supernatant and pelleted exosomes were subjected to sodium carbonate treatment upon which 
2
assayed for HIV-1 LTR suppression activity.  HIV-1 LTR suppression activity was readily 
detected in TG exosomes as well as dI-ddH2O and sodium carbonate extracts made from the TG 
exosomes (Figure 21A).  In the H9 exosomes, however, little to no soluble extraction of the LTR 
suppression activity was found in either dI-ddH2O or sodium carbonate extracts made from H9 
exosomes despite considerable suppression of the HIV-1 promoter by H9 exosomes after each 
extraction (Figure 21A).  The extent of soluble vs. membrane-bound antiviral activity for TG 
exosomes was comparable (44% vs. 70%, respectively, after dI-ddH2O extraction and 60% vs. 
45%, respectively, after sodium carbonate treatment), whereas H9 exosomes demonstrated a 
much greater discrepancy between soluble and membrane-bound LTR suppression activities (0% 
vs. 33%, respectively, after dI-ddH2O extraction and 7% vs. 65%, respectively, after sodium 
 and TG exosome samples, this time reversing the soluble extractions, 
subjecting samples first to sodium carbonate treatment followed by overnight extraction in dI-
carbonate treatment).  To confirm this apparent difference, a second analysis was performed on 
second set of H9
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ddH2O at 4°C.  LTR suppression activity was assessed for the soluble fractions and results 
demonstrated an apparent restriction in the specificity of extraction for the soluble antiviral 
activity to TG exosom
LTR suppression activity, respectively, for the same extractions (Figure 21B).  Aliquots of the 
 
 
 
 
 
es but not H9 exosomes (Figure 21B). Soluble extracts from TG exosomes 
displayed 45% and 39% LTR suppression activity, respectively, after sodium carbonate and dI-
ddH2O treatments, whereas soluble extractions from H9 exosomes only resulted in 1% and 17% 
dI-ddH2O made in this second experiment were consequently stored at -70°C for further analysis. 
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A. 
 
 
 
 
 
B. 
 
 
Figure 21.  Soluble extractions from H9 and TG exosomes.  (A) A step wise extraction 
procedure consisting of ddH2O extraction in the first step and sodium carbonate in the 
second step, assaying aliquots after each procedure for supernatant and exosome LTR 
suppression activity.  (B) Analysis of soluble fractions after the order of extractions is 
reversed with sodium carbonate as a first step and ddH2O in the second.  The step 2 
ddH2O fraction shown in (B) was used for analysis by MALDI-TOF-MS. 
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3.4.4 LDI-TOF-MS analysis of dI-ddH2O-eluted fractions from H9 and TG exosomes 
The finding that soluble extraction of the LTR suppressing activity was largely restricted 
to TG exosomes suggested that soluble fractions made from H9 exosomes could serve as an ideal 
control for differential proteomic analysis of dI-ddH2O-solublized extracts.  The proteomic 
analysis technique of matrix assisted laser desorption ionization-time of flight mass spectrometry 
(MALDI-TOF-MS) was employed to determine if differences in LTR suppression activity could 
be attributed to differential MALDI-TOF-MS analyte signals produced from proteins in the dI-
ddH2O extracted samples. The dI-ddH2O extracted TG and H9 samples described in Figure 22B 
were analyzed by MALDI-TOF-MS using an Applied Biosystems DE-PRO Voyager Mass 
pectrometer.  In the resulting spectra, a mass/charge (m/z) range between m/z 5.0 and 14.0 kDa 
mmon analyte signals between the TG and H9 
samples (Figure 22A and 22B, respectively).  A common triplet of signals was observed at m/z 
11.3, 11.7, and 12.2 kDa in both the TG and H9 solublized samples.  The m/z 11.3 kDa analyte 
was chosen to serve as an internal control in an attempt to identify differential analyte signals 
between the TG and H9 samples.  Since the samples analyzed were standardized for volume and 
were extracted from their exosome sources at equivalent exosome protein concentrations, 
differentially displayed analyte peaks relative to an internal control should reflect the relative 
levels of the protein giving rise to a particular peak.  Of particular interest were MALDI-TOF-
S signals that were at higher levels in the TG sample than in the H9 sample re tive to the m/z 
MA
S
was analyzed to identify differential and co
M la
11.3 kDa signal designated as an internal control.  One such signal at m/z 8.6 kDa appeared to 
stronger in the TG spectra than for the H9 spectra.  The ratio of the peak integration values of the 
m/z 8.6 kDa signal to the m/z 11.3 kDa signal corresponded strikingly with the differential LTR 
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suppression activity observed between the TG and H9 dI-ddH2O extracted samples (Figure 
22C). 
A. 
 
 
 
B. 
 
 
        C.           
           
Figure 22.  MALDI-TOF-MS analysis of the ddH
 
MALDI-TOF-MS mass to charge spectra of TG exosome ddH2O-extracted fraction. (B) 
Analyte signals corresponding to approximately m/z 8.6 kDa and m/z 11.3 kDa are denoted 
m/z 8.6 kDa to m/z 11.3 kDa peak integration values shown in the graph on the left 
compared to LTR suppression activity in the graph on the right. 
2O fraction from Figure 21.B.  (A) 
MALDI-TOF-MS mass to charge (m/z) spectra of H9 exosome ddH2O-extracted fraction.  
in the spectra along with peak integration values in brackets (A and B).  (C) The ratio of 
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The MALDI-TOF-MS analysis was extended to a larger panel of dI-ddH2O extractions 
from five TG and two H9 exosome samples.  The seven dI-ddH2O extracted samples displayed a 
divergent range of LTR promoter suppression activity (Figure 23).  MALDI-TOF-MS analysis 
was performed on the seven samples (Figure 24).  The triplet signals of m/z 11.3, 11.7, and 12.2 
kDa were found in all seven dI-ddH2O extractions, validating their use as internal controls.  In 
addition to the m/z 8.6 kDa signal, differential signals of m/z 5.0, 5.4, and 6.2 kDa were also 
identified that appeared to correspond with the HIV-1 suppressing activity for each sample.  
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Figure 23.  Panel of five TG and two H9 dI-ddH2O extracted samples with a divergent 
range of LTR suppression activity.  The samples are arranged here in rank order from 
ighest to lowest antiviral activity. h
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Figure 24.  MALDI-TOF-MS analysis of the five TG and two dI-ddH2O extracted samples.  
The samples are arranged here in order of highest activity to lowest:  TG A > TG B > TG C 
> H9A > H9 B > TG D > TG E.  (continued on p.97). 
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Figure 24.  (continued from p.96) 
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Figure 25.  Relative effective concentration of proteins corresponding to various 
MALDI-TOF-MS analyte signals among five TG and two H9 dI-ddH2O extracted samples
hown here are effective concentrations values for (A) m/z 5.0 kDa, (B) m/z 5.4 kDa, (C) 
/z 6.2 kDa and (D) m/z 8.6 kDa analytes.   
 
Since MALDI-TOF-MS analyte signals correspond to proteins contained in the original 
exosome extracts, relative peak integrations standardized by the m/z 11.3 kDa internal control 
signal as well as the original exosome protein concentration during dI-ddH2O extraction of the 
.  
S
m
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fractions describe the relative concentration of a protein giving rise to a specific mass/charge 
signal. Calculation of relative protein concentrations corresponding to the m/z 5.0, 5.4, 6.2 and 
8.6 kDa signals (Figures 25A-D) were striking in their correspondence to the LTR suppression 
activity (Figure 24) for the panel of dI-ddH2O extracted samples analyzed.  Interestingly, the 
relative proportions of the m/z 5.0, 5.4, 6.2, and 8.6 kDa appeared in relatively conserved 
proportions averaging a ratio of 3 : 1 : 1 : 2 for samples displaying significant HIV-1 suppression 
activity (Table I). This would further identify these four analytes as a functional set, 
guishing them from other signals such as .3 kDa, which appear invariant to LTR 
ls thus serves as valuable markers 
indicating the presence of a soluble protein mediating HIV-1 transcriptional suppression. 
 
 
Table 1.  A generally conserved ratio of 3:1:1:2 for the m/z 5.0, 5.4, 6.2, and 8.6 kDa 
MALDI-TOF-MS signals from the dI-ddH2O extracted samples displaying significant LTR 
suppression activity.  (i) The m/z 5.4 kDa signal used as the normalizing factor.  (ii) The m/z 
6.2 kDa signal used as the normalizing factor. 
 
(i) Sample             Relative Ratio 
______________5.0 kDa/z    5.4 kDa/z  6.2 kDa/z       8.6 kDa/z
distin  the m/z 11
suppression activity.   The m/z 5.0, 5.4, 6.2, and 8.6 kDa signa
 TG A      3.240964            1  1.018072         2.230924 
TG B      2.702479                1            1.024793         2.427686 
 B C          3.444444            1  1.160494  2.345679 
 H9 A      2.428954            1  0.780161  1.123324 
 
T
 
ative Ratio 
______________5.0 kDa/z    5.4 kDa/z  6.2 kDa/z       8.6 kDa/z
Average     2.954211            1  0.99588  2.031903 
 
 
(ii) Sample             Rel
 TG A      3.183432    0.982249              1               2.191321 
 G B      2.637097    0.975806              1               2.368952 
 TB C          2.968085        0.861702              1               2.021277 
 
T
H9 A      3.113402        1.281787              1               1.439863 
 
 
Average     2.975504    1.025386         1   2.005353 
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3.5 DISCUSSION 
uncovered in the previous chapter of study (Chapter 2). The discovery of HIV-1 suppressing 
exosomes secreted by TG cells was a seminal development for the inquiry presented here, as it 
large enough scale to probe the molecular nature of the elusive antiviral effector mechanism of 
mediated nature for secreted CD8+ cell antiviral activity was the starting point for this 
investigation to determine if a mechanistic connection existed between the two components of
 
The investigation described here was undertaken based on some specific results 
represented a novel source of HIV-1 transcription suppression activity that could be purified at a 
CD8+ T cells. The previous demonstration in Chapter 2 of a dual soluble factor- and exosome- 
 
AF activity. The present investigation began by attempting to detect fluctuations in the potency 
vity on the surface of exosomes. U ysis of various exosome-depleted TG 
an se correlation was 
es present in TG 
re is res s e idea of the soluble factor being derived from a 
olecule expressed on TG exosomes and consequently provided an alternative interpretation 
r t erved in exosome-
ediate -  transc
 was a is anner in which 
e HIV-1 LTR suppressive activity localized to the membrane of TG exosomes in order to begin 
C
of exosome-mediated LTR suppression activity. Using careful quantification methods, results 
from this first set of experiments readily detected fluctuations in LTR promoter suppression 
acti pon side-by-side anal
culture fluids and exosomes purified from the  apparent pattern of inverm, 
observed between exosome-media d and m ane free an iral activitite embr tiv
cultu  fluids. Th ult was consi tent with th
m
othe phan simple variable gene expression to ex lain the fluctuations obs
m d HIV 1 ription suppression activity. 
 
An effort ccordingly undertaken in th study to define the precise m
th
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probing the possible mechanism by which the antiviral activity expressed on the external surface 
of exosomes might be converted into a soluble form. Salt-extraction experiments performed in 
this study dem
property of both a membrane-bound and membrane-free molecule despite exhaustive sodium 
soluble form, namely the potential presence of some secondary enzymatic activity in TG 
was observed after subsequent dI-ddH O extraction than what was found in the previous sodium 
 
 of this analysis uncovered several analyte 
signals corresponding with the LTR suppressive activity of the set of fractions studies.  This 
would indicate the presence of specific proteins
suppressing exosomes, eluted into solution by simple water extraction after depletion of 
onstrated for the first time that a soluble antiviral factor could be extracted from 
the exosomes themselves. A striking result in the ensuing investigation was the finding that the 
LTR suppressive activity exhibited a curious partial solubility from TG exosomes, exhibiting the 
carbonate treatment of TG exosomes. This was especially demonstrated in carefully controlled 
soluble extraction experiments of H9 and TG exosomes, where the property of solubility was 
observed to be largely restricted to TG but not H9 exosomes.  Such a result strongly implies a 
non-random mechanism by which the membrane-bound antiviral factor is converted into a 
exosomes functioning in the cleavage of a membrane-bound HIV-1 transcription suppressing 
factor off its molecular anchor to produce a soluble active antiviral protein fragment. Indeed, in 
one experiment, after sodium carbonate depletion of peripheral proteins from two independent 
TG exosome samples, a significantly higher level of HIV-1 transcription suppressive activity 
2
carbonate treatment (Figure 21).   
These findings were further corroborated by MALDI-TOF-MS analysis of various dI-
ddH2O extracts from TG and H9 exosomes.  Results
 or protein fragments released from HIV-1 
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peripheral membrane proteins from exosomes.  That an apparent defined ratio between a set of 
MALDI-TOF-MS signals appeared preserved across independent HIV-1 suppressing soluble 
samples further suggests a specific non-random event giving rise to the solublized factors 
producing the observations described. One of these signals could very well originate from the 
elusive solublized factor mediating suppression of HIV-1 transcription.  In addition, the number 
of analyte signals detected corresponding to LTR suppression activity and their non-equivalent 
proportions in each soluble extract sample, further hints at more than one protein source 
correlating with LTR suppression activity. This would be another inference to a non-random 
activity involved in releasing such molecules from their membrane tethering.  These results 
strongly suggest the existence of a specific proteolytic or enzymatic activity in releasing the 
antiviral activity mediating transcriptional suppression of HIV-1 (Figure 26), a postulate that is 
consistent with indirect evidence presented by other investigators of protease inhibitor 
modulation of both CAF and CD8+ cell-mediated HIV-1 suppression (215). 
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LTR promoter suppression factor and its experimental verification.  This model postulates 
undergoes a proteolytic event that cleaves a fragment containing the LTR suppressive 
 
he possible presence of a proteolytic action releasing a membrane-free form of HIV-1 
transcription suppression activity from a membrane-bound precursor would elegantly explain the 
results observed in this study and reconcile the dual exosome and soluble factor components 
found for secreted CAF activity in the previous chapter.  If a proteolytic activity of this nature 
does indeed exist, then a number of properties for such a putative catalyst can be predicted based 
on the results of this study. Firstly, the secondary factor would be predicted to exist in a 
membrane-bound form as sodium carbonate depletion of peripheral proteins did not prevent 
recurring formation of an extractable soluble antiviral factor.  Secondly, a putative enzymatic 
cleavage activity of this nature would also be expected to colocalize with the same exosome 
proteins as the LTR suppressive factor, such as the tetraspanin molecules found localized on 
exosomes (Figure 5, Chapter 2). A potential autolytic cleavage activity on a membrane-bound 
Figure 26.  A proposed model for the concurrent membrane-bound / soluble nature of the 
an integral membrane protein mediating HIV-1 LTR promoter suppression (1) that 
activity (2) which is released as a soluble factor (3). 
 
T
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HIV-1 suppressing protein can perhaps be ruled out as H9 exosomes readily demonstrate 
membrane-bound antiviral activity with little to no soluble fragment mediating the same action, 
implying the requirement of a secondary factor for releasing the antiviral activity from a 
membrane anchor.  If a protease is involved in cleaving an HIV-1 suppressing precursor into a 
soluble form, then its presence can potentially be probed through the use of protease inhibitors to 
determine if disruption of proteolytic activity is coincident with non-extraction of a soluble 
fragment.  If such a result was found, not only would it elegantly explain many of the results in 
this investigation, but it would also be consistent with the biogenesis of HIV-1 exosomes from 
within late endosomes, an intracellular compartment that functions in general degradation of 
 action in modulating the factor mediating 
LTR promoter suppression activity provides an interesting avenue to explore noncytolytic CD8+ 
T cell 
extracellular membrane protein.  
 
While the possible involvement of a proteolytic
suppression of HIV-1, the most exciting result of this investigation is, perhaps, the 
development of novel techniques in this study for the serum-free purification of the HIV-1 
suppressive activity into pure water.  Although such a result may appear trivial at first glance, it 
represents an unprecedented advancement in the 20 year quest to identify the molecular factor 
mediating this potent but elusive antiviral activity. Previous attempts at purifying this activity 
have utilized methods attempting to harvest the soluble protein from bulk quantities of filtered 
culture media.  Even when grown under serum free conditions, the presence of large quantities of 
recombinant growth factors in serum-free culture media make biochemical purification of the 
antiviral factor problematic, especially given that the antiviral activity appears typically secreted 
in low quantities.  While exosomes are also harvested from bulk culture media, results from the 
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investigation performed here have demonstrated that the activity mediating HIV-1 transcriptional 
suppression remains intact after exosome purification and multiple biochemical treatments, 
allowing for elution of water soluble fractions of the activity towards protein identification. 
Utilization of HVS-transformed CD8+ T cell lines for exosome harvesting allows for 
theoretically unlimited scalability for production of water eluted fractions containing high 
concentrations of HIV-1 transcription suppression activity.  
 
In the quest for ultimate protein identification of the elusive HIV-1 transcription 
suppressive factor produced by CD8+ T cells, several techniques described in our investigation 
will greatly aid in such an endeavor.  MALDI-TOF-MS represents only a first tier method for 
more advanced proteomic methods such as protein chip profiling, ion-trap MALDI-TOF/TOF-
MS/MS and electrospray injection-based multidimensional proteomic profiling.  The 
identification of specific MALDI-TOF-MS analyte signals is particularly promising for 
application of the more advanced ion-trap MALDI-TOF/TOF-MS/MS, as this technique utilizes 
capture of specific ion masses towards direct sequence evaluation.  Such a procedure would not 
only be valuable in identifying potential candidate molecules identifying with the HIV-1 
suppressive activity, but perhaps also identify possible exosome markers co-localizing with the 
antiviral factor to further define its intracellular regulation and manifestation at a cellular level.  
The utility of traditional biochemical fractionation techniques such as HPLC and gel filtration is 
now made feasible with procedures outlined in this study for larger scale production of the 
solublized antiviral activity.  Such fractionation techniques combined with biological evaluation 
using the acute LTR suppression assay described here can facilitate more conclusive 
interpretations of proteomic data.  The techniques and results presented in this chapter of study 
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represent a major leap forward in bringing to fruition conclusive identification of the molecular 
factor mediating HIV-1 transcription. 
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4.0  FINAL DISCUSSION AND  CONCLUSIONS 
Before undertaking the study presented here, there were several lines of evidence that 
suggested a greater complexity to the antiviral mechanism behind CD8+ T cell noncytolytic 
HIV-1 suppression activity than a simple cytokine release model.  One was the greater potency 
of cell-contact mediated noncytolytic HIV-1 suppression (181,183) and the second was 
dissociation between cell-mediated suppression of HIV-1 and secretion of a soluble antiviral 
factor (183,185).  These results from previous investigations of the antiviral mechanism 
demonstrated that cell-contact played an important role in mediating the antiviral activity.  These 
findings were never investigated more thoroughly by other investigators, save for a handful of 
studies evaluating the involvement of molecules known to play a role in antigen-dependent 
CD8+ T cell responses (202-205). Therefore the role of membrane determinants in mediating the 
antiviral activity remained largely unexplored, despite clear evidence of cell-contact modulation 
of the activity.  What has ensued in the field was an effort by several groups to identify secreted 
mediator, CAF. While the many candidate molecules proposed did display HIV-1 antiviral 
activity (139,194-196), none of them were found to identify with the hallmarks of secreted CAF 
activity (197-200).  As a result, lack of any clear identification of a single responsible element 
led some groups to propose a hypothesis that noncytolytic suppression of HIV-1 by CD8+ T 
cells is largely mediated by a multifactorial secretion of antiviral molecules (195,201).  The 
results of the study presented here strongly refute this hypothesis. 
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 A multifactorial cytokine secretion hypothesis for CD8+ T cell noncytolytic HIV-1 
suppression not only ignores two key lines of evidence demonstrating the involvement of cell 
surface molecules, i
represent the “Achilles’ heel” for HIV-1:  the specific inhibition of lentiviral transcription by 
CD8+ T cells (172,177,186-190).  Therefore, the pres
a cleaved precursor since it was consistent with our initial analysis demonstrating an integral 
t dilutes the involvement of one key effector mechanism that may very well 
ent course of study was based on a central 
thesis that the specific factor mediating transcriptional suppression of HIV-1 is a membrane-
bound protein and in the ensuing study new evidence was uncovered strongly suggesting that 
CD8+ T cell suppression of HIV-1 transcription, including the secretion of an antiviral effector, 
is a phenomenon mediated by a specific membrane-bound protein activity.  The novel discovery 
that exosomes potently suppress transcription of HIV-1 in acute and chronic models of infection 
finally provides a key to defining a functional link between a cell surface antiviral protein and a 
secreted antiviral factor.  Initial observations of CD8+ T cell culture fluids suggested that CAF 
was basically composed of two components: (i) CD8+ T cell secreted exosomes that suppressed 
HIV-1 transcription and (ii) a soluble factor that also suppressed HIV-1 transcription.  That both 
mediated the same antiviral action prompted an investigation into whether these distinct 
components had a common molecular determinant.   
 
Initial characterization of TG membrane and secreted vesicles in Chapter 2 revealed that 
the responsible factor mediating suppression of HIV-1 replication was an integral membrane 
protein that could express itself on the external surface of exosomes and could exert its antiviral 
action independently of its lipid anchoring.  Upon discovery of a soluble protein mediating the 
same transcriptional suppression as exosomes, the most rational hypothesis to explore was that of 
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membrane antiviral factor.  Through a careful series of solvent extraction analysis described in 
Chapte
 findings in this study support a new model 
of CAF secretion, one that is an exosome-driven phenomenon with the appearance of a soluble 
protein
r 3, clear evidence of an HIV-1 transcription suppressing integral membrane factor being 
converted into a soluble form was found.  By pre-treating exosomes with sodium carbonate to 
deplete the vesicles of all peripheral proteins, water soluble extracts of specifically cleaved 
proteins from membrane-bound precursors could be made.  Application of MALDI-TOF 
revealed the presence of more than one protein that correlated with the released LTR suppression 
activity.  Furthermore, the release of the soluble antiviral factor was due to the presence of a 
second membrane-bound enzyme, as determined in a comparison of H9 and TG exosomes, 
which functions in the cleavage of a characteristic set of proteins, including the HIV-1 LTR 
promoters suppressing factor.  A characteristic signature of that enzymatic activity could be 
defined by MALDI-TOF-MS analysis.  Therefore, in an effort to define the LTR suppressing 
protein factor, a molecular mechanism was uncovered that elegantly explained the inverse 
correlations observed between the appearance of a soluble protein in CD8+ T cell culture fluid 
suppressing HIV-1 transcription and a tight association of the antiviral activity to exosomes.  The 
results of this study strongly refute a multifactorial cytokine secretion model for CAF and 
suggest instead a novel and elaborate membrane-mediated mechanism underlying secreted CAF 
activity and cell-mediated suppression of virus.  The
 factor being the consequence of an exosome-localized integral membrane converting the 
membrane-bound HIV-1 transcription factor into a soluble form.  In this new model, between an 
exosome-bound and soluble form of the same antiviral protein that comprises secreted CAF 
activity. 
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Such a distinction between a membrane-bound and membrane-free antiviral mediator 
may have important physiological consequences.  Recent studies in the exosome field have 
demonstrated a remarkable adhesion capability of exosomes to cell surfaces (233).  If such an 
engagement occurred with CD4+ cell surfaces by CD8+ T cell exosomes, it may facilitate 
specific engagement of the LTR suppressing factor with its cognate receptor to induce potent 
inhibition of proviral transcription.  Conceivably, the converse might be true where a soluble 
mediator may have greater conformational freedom than a membrane bound factor for engaging 
a cognate receptor on CD4+ cells.  The physiological role of a CD8+ cell-secreted mediator in 
suppressing HIV-1 transcription awaits further dissection.  However, the evidence uncovered in 
this study of a specific molecular factor secreted via exosome biogenesis indicates a much more 
complex nature to noncytolytic HIV-1 suppression by CD8+ T cells than previously thought 
(215). 
 
 Evidence outlined in this study of an integral membrane factor with potent LTR promoter 
inhibition activity opens a new door to finally understanding cell-contact mediated CD8+ T cell 
suppression of HIV-1.  The secretion of this antiviral protein via exosomes defines a very unique 
membrane microdomain the LTR suppressing protein factor colocalizes with.  While the 
identification of the LTR suppressing factor is an area of active research at the present, 
identification of the molecules colocalizing with the membrane-bound anti-HIV factor can 
greatly illuminate how such a factor is regulated by CD8+ T cells, particularly in dissecting the 
events that lead to the apparent priming of the noncytolytic HIV-1 suppression activity and its 
deficiency in HIV-1 patients rapidly progressing to AIDS.  The findings of HIV-1 suppressing 
xosomes secreted by CD4+ T cells underscore the point that simple expression of the antiviral e
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gene pr
mediators in the dynamic reorganization of T cell surfaces during antigen recognition 
36,237).   
oduct may not necessarily translate into cell-mediated activity.  In the context of cellular 
regulation, it can perhaps now be understood why noncytolytic HIV-1 suppressing CD8+ T cell 
clones are typically found displaying an HLA-DR+/CD28+ activated phenotype (176).  Such a 
phenotype is indicative of a dynamic re-organization of cell membrane protein, particularly the 
translocation of endosomal membrane compartments to the cell surface, especially with 
increased granule release that is characteristic of CTL activity.  In B cells and DCs, HLA-DR has 
been found to specifically associate with CD9, CD63, and CD81 tetraspanins (234,235) which 
are molecules we found specifically expressed on HIV-1 suppressing exosomes.  Thus, the 
tetraspanin colocalization with the HIV-1 suppressing activity in exosomes may provide clues as 
to how the factor might be regulated in CD8+ T cells.  Tetraspanin organization in CD8+ T cells 
has not been well studied.  However, recent reports have described tetraspanin protein webs as 
critical 
(2
 
Such a role for tetraspanin protein networks have been found in other cells as well, 
particularly in reshaping the cell surface and driving agglomeration of molecules into high 
concentration at points of cell-to-cell contact, with such processes occurring prior to and 
independently of MHC molecule-T cell receptor engagement (238).  This MHC-independent 
membrane reorganization might represent the vehicle by which cell-contact mediated LTR 
suppression is effected by CD8+ T cells.   Such a mechanism would presumably allow for 
physical aggregation of the HIV-1 suppressive factor on the surface of CD8+ T cells and 
therefore a more concentrated signaling for induce more potent suppression of proviral 
transcription (Figure 28.A).  In contrast, a fluid mediator driven by exosome secretion, composed 
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of exosome- and soluble-mediating components, might only deliver weak to moderate signals to 
suppress HIV-1 transcription due to the diffusible nature of the secreted activity (Figure 28.B).  
Our findings of LTR suppression activity co-localizing with tetraspanin protein networks may 
finally resolve the dissociation observed between secreted- and cell contact-mediated forms of 
noncytolytic HIV-1 suppression displayed by CD8+ T cells.  
 
A.       B. 
                  
 
Figure
localize
 
 Identification of the LTR suppressing molecule would aid immensely in unraveling the 
mechanism behind potent HIV-1 transcriptional suppression by CD8+ T cells.  The paradigm of 
a membrane-localized nature for the antiviral activity has led to the development of novel 
methods for purifying concentrated fractions containing the activity.  The elution of the activity 
from a serum free source will greatly facilitate conclusive identification of the activity.  In 
 27.  A model for CD8+ T cell suppression of HIV-1 transcription by a membrane-
d antiviral factor.  (A) Cell-contact mediated CD8+ T cell suppression of HIV-1 
might involve a purely membrane-bound factor that induces potent HIV-1 transcription 
inhibition due to a possible tetraspanin-dependent clustering.  (B) A fluid mediator is 
driven by exosome secretion where the antiviral factor mediates LTR suppression either 
bound to the exosome or a cleaved soluble fragment. 
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addition, immunophenotyping of exosomes by the immunomagnetic bead capture can allow for a 
more comprehensive understanding of the factors that might regulate the LTR suppressive factor 
at the cell surface and in the secreted vesicles.  The evidence presented in this study of a 
suggested protease activity colocalizing to HIV-1 suppressing exosomes may be just one 
example of this antiviral factor’s intracellular regulation.  Further dissection of the exosomes by 
lobal proteomic profiling techniques, such as MuDPIT (246), can provide a much more 
g with and possibly regulating the 
HIV-1 suppressive factor.  The results of this study have provided a much needed illumination 
on the true nature of this enigmatic but potent CD8+ T cell effector function against HIV-1 
replication.  Future study of how CD8+T cells inhibit HIV-1 transcription can now be 
approached with greater clairvoyance.  
g
comprehensive analysis of the network of proteins associatin
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